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ABSTRACT 
Insights into the cyclooxygenase pathway in a progressive rat model of Parkinson’s disease 
induced by prostaglandin J2: protection with ibuprofen 
by 
Chuhyon Corwin 
 
Advisor: Dr. Maria E. Figueiredo-Pereira 
 
Parkinson’s disease (PD) is a neurodegenerative disease with aging as a major risk factor. 
Its defining symptoms are motor deficits that are primarily associated with dopaminergic 
neuronal loss in the substantia nigra pars compacta (SNpc) in the midbrain. Post-mortem PD 
brains exhibit abnormal intraneuronal inclusions of α-synuclein and ubiquitinated protein 
aggregates known as Lewy bodies, a hallmark of PD pathology.  
Currently, there is no validated biomarker for PD. Especially the early stage of PD is 
difficult to detect as the pathology develops progressively. While symptom-managing treatments 
are available, there is no neuroprotective treatment as of yet, mainly due to the unknown cause of 
PD. Animal models of PD have greatly expanded our knowledge on different aspects of PD. 
However, each has challenges on closely mimicking PD’s major pathological conditions, 
especially the progressive nature of the pathology. Among the existing PD animal models, a 
shared feature is neuroinflammation, which has been increasingly implicated in the development 
of PD by findings from genome-wide association studies, PD-risk genes, environmental risk 
factors and post-mortem studies. Transition of acute neuroinflammation to the chronic state is 
critical in the development and worsening of neurodegeneration associated with inflammation.  
v 
 
The cyclooxygenase (COX) pathway is a major contributing factor to the development of 
PD. Firstly, COX-2 is upregulated in the substantia nigra of PD patients. Secondly, existing 
genetic and toxin models of PD indicate the involvement of the COX pathway. Thirdly, 
epidemiological studies report the effect of non-steroid-anti-inflammatory drugs (NSAIDs) in 
lowering PD risk. However, NSAIDs are not an ideal treatment against PD due to their serious 
side effects. Prostaglandins are products of the COX pathway but their profile and role in the 
progression of PD pathology are not fully understood. As endogenous products of 
neuroinflammation, prostaglandins may be highly relevant to the etiology of PD.  
The overall goal of my studies was to gain insights into how prostaglandins contribute to 
PD neurodegeneration in vivo.  
Goal 1: Establish a rat model of neuroinflammation displaying parkinsonian-like 
pathology induced by the highly neurotoxic prostaglandin J2 (PGJ2), and characterize the 
impact of PGJ2 on key factors of the PGD2/J2 signaling pathway (Chapter 2).  
We found that unilateral nigral PGJ2-microinfusions induced progressive PD-like 
pathology in the rats. PGJ2-treated rats exhibited dose-dependent and progressive dopaminergic 
neuronal loss in the SNpc, correlated motor deficits, and gliosis involving microglia and 
astrocytes. Ibuprofen, an NSAID, prevented most of the PD-like pathology shown in PGJ2-
treated rats. 
We explored the effect of PGJ2-treatment on COX-2, lipocalin-type PGD2 synthase (L-
PGDS), PGD2/J2 receptor 2 (DP2), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a 
PG-deactivating enzyme. We found that COX-2, L-PGDS, and 15-PGDH levels increased 
significantly in PGJ2-treated rats compared to controls in the SNpc DA neurons. DP2 receptors 
were found predominantly expressed on dopaminergic neurons. The levels of COX-2 and L-
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PGDS co-localization in microglia were increased upon PGJ2-treatment. However, 15-PGDH 
levels were did not differ among all rat groups, while high levels of 15-PGDH were detected in 
SNpc oligodendrocytes.  
Goal 2: Assess chronic neuroinflammation in the PGJ2-induced rat model in vivo 
with micro-PET imaging (Chapter 3).  
We performed µPET imaging with the translocator protein (TSPO) radioligand 
[11C]PK11195 at two different time points (weeks four and eight), post DMSO and PGJ2-
injections. Higher [11C]PK11195 uptake was observed in rats that received two PGJ2-injections 
compared to controls (DMSO-treated) at both time points,  indicating  chronic glial activation.  
Conclusion: our studies establish that the PGJ2-induced rat model recapitulates the 
progressive nature of PD pathology albeit in a relatively short term. Chronic neuroinflammation 
exhibited in the PGJ2 rat model of PD was assessed with PET imaging in vivo. Studies with the 
PGJ2-induced rat model of PD have potential to identify and optimize treatments against 
neurotoxic inflammation, and to evaluate novel PET radiotracers for neuroinflammation. Our 
studies with the PGJ2-induced rat model of PD, strongly support that therapeutic targets 
downstream of cyclooxygenases, such as DP2 receptors and L-PGDS, have potential against PD 
pathology.  
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CHAPTER I 
 
INTRODUCTION 
 
1.a. Parkinson’s disease and neuroinflammation 
1.b. Prostaglandin J2 as an endogenous product of the cyclooxygenase pathway  
1.c. Advantages of developing a rat model of neuroinflammation that develops 
parkinsonian-like pathology 
 
 
Chuhyon Corwin 
 
Department of Biology, 
Hunter College of the City University of New York, 
New York, New York 10065 
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1.a. PARKINSON’S DISEASE AND NEUROINFLAMMATION 
1.a.1. An overview of Parkinson’s disease 
Parkinson’s disease (PD) is the second-most common form of neurodegenerative disorder, 
affecting one in 100 people over age 60. PD is a chronic disease that slowly progresses over the 
years and its progression rate highly varies among individuals until symptoms reach irreversible 
milestones such as postural instability, dementia and death 4 and its diagnosis is confirmed post-
mortem. 
PD pathology is characterized by the progressive loss of dopaminergic (DA) neurons in 
the substantia nigra pars compacta (SNpc) and the presence of neuronal protein aggregates 
known as Lewy bodies that include α-synuclein and ubiquitinated proteins. DA neuronal loss in 
the SN is mainly responsible for the defining motor symptoms of PD, such as bradykinesia and 
muscular rigidity, but it is not the only factor attributed to PD pathology. As the disease 
progresses, non-DA neurons also degenerate and the affected brain region exceeds the area of the 
SN. Neuronal protein aggregates are found in various regions of the brain. Thus, patients with 
PD also experience non-motor symptoms involving sleep and the olfactory, autonomic, sensory 
and pain systems (reviewed in 5 and 6). However, how the disease spreads to other brain regions 
is not clearly determined and is being investigated in two main directions: by propagation 
through synaptic connectivity throughout the brain network, or by cell or region-specific 
vulnerability 7;8. 
There are two major approaches in the treatment of PD: symptomatic and neuroprotective. 
For the symptomatic therapy, L-3,4-dihydroxyphenylalanine (L-dopa), the precursor of 
dopamine, remains as the gold standard since the 1960s. As the PD motor symptoms appear 
when the dopamine level in the brain is reduced by 70-80% 9, L-dopa alleviates motor symptoms. 
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However, L-dopa is not disease-modifying, therefore DA neuronal degeneration continues as PD 
pathology progresses. In addition to medication alone, deep brain stimulation (DBS) can be used 
for further improvement in motor symptoms. Though DBS has been used for PD for three 
decades, its exact mechanism is unknown and it is accompanied by complications involving the 
surgeries 10. Among surgical strategies, stem cell and reprogrammed cell transplantations are 
considered as neuroprotective treatments to restore DA neuronal degeneration. However, there 
are still major challenges to overcome including the safety concern and potency of the treatment 
11
. With multiple failures of pharmacological treatments in the later-stage of clinical trials, most 
recently by Phytopharm in 2013 12 and Acorda Therapeutics in 2017 13, neuroprotective 
treatments to slow or reverse PD progression remain nonexistent. 
In the meantime, various non-pharmacological treatments, such as exercise, are being 
explored to improve the quality of life of PD patients 14. Moreover, the growing number of failed 
attempts to develop neuroprotective treatment is being attributed to the need for (a) improved 
preclinical animal models to advance the understanding of the heterogeneous PD pathology 
throughout the disease progression, and (b) effective evaluation means of diagnostics as well as 
therapeutics. 
1.a.2. Neuroinflammation and PD 
Neuroinflammation is a localized defense response of the nervous tissue to a variety of 
cues including traumatic brain injury, stroke, infection, and toxic metabolites. 
Neuroinflammation is also a non-specific response as it always results in microglia and astrocyte 
activation independently of the initiating cue. Acute inflammation is resolved immediately after 
the injured site is healed. However, neuroinflammation is widely regarded as chronic 
inflammation of the central nervous system (CNS) that extends beyond the original injury and 
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spreads to healthy areas. 
While there is no wide consensus yet on the exact cause of PD, genetic and 
epidemiological studies confirm that neuroinflammation plays a critical role in the 
neuropathology and progression of PD. Firstly, genetic factors are thought to be related to 
neuroinflammation. Genome-wide association studies (GWAS) reported that variations in loci 
encoding immune-associated genes such as human leukocyte antigen (hla), bone marrow stromal 
cell antigen 1 (bst1), and triggering receptor expressed on myeloid cells 2 (trem2) are genetic 
risk factors for PD 15;16. In addition, PD-associated mutations in the genes α-synuclein, lrrk2 
(leucine-rich repeat kinase 2), parkin and pink1 (PTEN-induced putative kinase 1) were shown 
to be linked to the inflammation regulatory pathway 15. α-Synuclein has become a topic of active 
research since its mutation was the first identified genetic factor linked to PD 17. For example, 
postmortem PD brains exhibit abnormally high level of α-synuclein, particularly the insoluble 
form 18. Moreover, α-synuclein overexpression and neuroinflammation enhance each other to 
drive chronic progression of neurodegeneration 19. Within Lewy bodies, α-synuclein reportedly 
undergoes post-translational modifications such as phosphorylation and ubiquitination. In 
particular, α-synuclein phosphorylation at residue S129 (pS129) has received much attention in 
recent years, since several studies reported that patients with synucleinopathies exhibit high 
accumulation of pS129 α-synuclein (reviewed in 20). Phosphorylation of α-synuclein at S129 
promotes the formation of soluble oligomeric α-synuclein that correlates with neurotoxicity 21. 
However, the mechanisms by which pS129 regulates α-synuclein function, and whether pS129 
negatively or positively contributes to PD pathogenesis are still being investigated. 
Secondly, environmental factors, such as toxins and lifestyle, are also related to 
neuroinflammation.  Factors associated with the increased risk of developing PD are pesticides, 
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trichloroethylene (an industrial solvent), methamphetamine, well-water, rural living, farming 
occupation, beta-blocker use, history of anxiety or depression, traumatic brain injury, and diet 
(reviewed in 22 and 23). 
Thirdly, the process of PD onset and progression is likely to involve apoptosis and 
oxidative stress, mitochondrial dysfunction, and altered protein processing, which all appear to 
be involved in neuroinflammation (for review see 24). 
Fourthly, compared to normal controls, the brains of PD patients exhibit significant 
increases in the numbers of activated microglia, astrocytes and T lymphocytes, as well as in the 
expression of cyclooxygenase (COX)-2 and other pro-inflammatory mediators 5;25-29. 
Neuroinflammation involves prolonged gliosis of microglia and astrocytes and 
infiltration of other immune cells such as T lymphocytes and peripheral dendritic cells into the 
brain by crossing a compromised blood brain barrier (BBB), thus perpetuating the immune 
response. Upon activation, both microglia and astrocytes undergo morphological changes. In 
addition, activated microglia and astrocytes release a broad range of inflammatory mediators that 
include eicosanoids, cytokines, chemokines, reactive free radicals and proteases. Some of these 
mediators are neuroprotective while others are neurotoxic, supporting the notion that 
neuroinflammation is a double-edged sword playing both detrimental and beneficial roles 
depending on the circumstances 30;31. 
Microglia - Microglia are distributed across all major brain regions, and are densely 
populated in the SNpc, taking up 12% of the local cell population 32. During development and 
aging, microglia carry out diverse functions in the normal and disease states of the CNS. Recent 
studies have expanded our understanding of the “resting-state” of microglia, as being actively 
involved in neuronal connectivity and synaptic plasticity (for review see 33). Nevertheless, 
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microglia are commonly known for the initiation of inflammation in response to CNS injury, 
infection, and pathology. Some studies suggest that activated microglia are beneficial to DA 
neurons by releasing neurotrophic factors 34;35. However, most findings support that activated 
microglia are harmful to DA neurons in the SNpc, as they release proinflammatory 
prostaglandins, cytokines, and chemokines, in addition to expressing high levels of COX-2 36;37. 
Astrocytes - Beyond the typical housekeeping role of maintaining the homeostatic 
environment for neuronal activity, astrocytes play other critical roles such as direct participation 
in synaptic transmission and neurovasculature modulation. Additionally, activation of astrocytes 
can be induced by brain injuries due to infection, trauma, ischemia or neurodegeneration and 
lead to scar formation in severe cases 38. During astrogliosis, astrocytes undergo changes in their 
morphology and molecular profiles. Reports on the extent of astrogliosis in the SN of PD brains 
are somewhat mixed (reviewed in 39), but findings of massive reactive astrocytes within the 
SNpc indicates a robust inflammatory state. 
Astrocytes are activated via their own intracellular mechanism, as well as by molecules 
released as results of microglia activation, leukocyte infiltration, neuronal degeneration and 
endothelial activation in response to injuries. Once astrocyte activation is triggered, it can be 
sustained by endothelin, growth factors and inflammatory molecules, leading to activation of 
inflammatory pathways including up-regulation of COX-2 and its derivatives 40. Our 
understanding of reactive astrocyte function is still limited. Whether activation of astrocytes 
serves neuroprotective roles or contributes to chronic inflammation is uncertain, as it depends on 
specific molecular signaling cascades being up- or down- regulated. Modulation of diverse 
molecules by reactive astrocytes varies with the type of astrogliosis trigger and with time after 
insult 38. Ongoing efforts are being made to characterize harmful and protective reactive 
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astrocytes as both types are induced by neuroinflammation. According to a study with 
lipopolysaccharide (LPS)-treated rodent postnatal cell culture and mice 41, activated microglia 
induce the neurotoxic type of reactive astrocytes that lost many normal astrocytic functions, and 
not the beneficial type of astrocytes in which many neurotrophic factors are upregulated. The 
number of the neurotoxic C3 (complement component 3) expressing reactive astrocytes is three 
times higher in the SN of PD brains 41. 
Recruitment of immune cells – The brain has long been classified as an “immune 
privileged” organ, separated from the periphery by the BBB. However, surveillance by the 
immune system is now recognized as a routine occurrence in the brain, even under healthy 
normal conditions. Changes in the numbers of immune cells such as leukocytes, T and B 
lymphocytes, monocytes, macrophages and dendritic cells, in the CNS require further 
investigation. However, it is certain that immune cells cross the BBB during inflammatory 
challenges (reviewed in 42). 
The BBB of PD brains is compromised and exhibits hyperpermeability 43, allowing 
increased infiltration of peripheral immune cells into the brain. PD postmortem studies revealed 
increased infiltration of CD4+ and CD8+ T cells in SNpc 28. Studies with 6-hydroxydopamine 
(6-OHDA), 1-methyl-1,2,3,6-tetrahydropiridine (MPTP) and LPS animal models replicated these 
findings on the integrity of the BBB and immune cell infiltrations 28;44;45. Emerging evidence 
supports that recruitment of peripheral immune cells, particularly T lymphocytes, contributes to 
PD pathology, but the mechanism of infiltration and its role in PD pathogenesis remains elusive 
(reviewed in 46;47). 
COX-2 – Compared to age-matched controls, PD brains exhibit higher expression of 
COX-2 in the SNpc 48. In addition, epidemiological studies indicate an inverse relation between 
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the use of certain non-steroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenases 
and the risk for developing PD. Although there are conflicting results in the relation between 
NSAID use and PD, the evidence for lowering the risk of PD is strongest for the use of ibuprofen 
5;49
. However, clinical studies have not consistently replicated the efficacy of NSAIDs, most 
likely because current NSAIDs have serious side effects and poorly cross the BBB 5. An 
improved understanding of the shared and specific mechanisms by which NSAIDs inhibit 
cyclooxygenases and reduce prostaglandin levels, is required to effectively target the 
cyclooxygenase pathway to treat PD. 
1.a.3. PD animal models 
There is a general consensus on the impact of certain environmental and genetic factors 
on PD pathology. Therefore, administration of toxins such as 6-OHDA, MPTP, rotenone, and 
paraquat, or genetic manipulation of α-synuclein, pink1, parkin, and lrrk2 genes have been used 
to model PD in animals. These models have contributed significantly to a better understanding of 
PD pathology, however none captures all of the PD hallmarks. There is still a need for improved 
models that mimic PD pathology, especially the progressive nature of DA neurodegeneration in 
the SNpc. Animal models that depict progressive development of PD, will advance PD diagnosis 
and prognosis. 
Progressive models of PD are required, to capture earlier stages of PD pathology with 
less severe DA neurodegeneration. Animal models of PD should display DA neurodegeneration 
and motor deficits similar to those exhibited by PD patients 50;51, but this is often not the case 
52;53
. For instance, PD models based on genetic risk factors, such as mutations in parkin, pink1 
and lrrk2, show little or no nigrostriatal degeneration and motor symptoms. Several 
pharmacological PD models, such as 6-OHDA, MPTP, paraquat and rotenone, exhibit motor 
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symptoms caused by rapid and severe degeneration of the nigrostriatal pathway, i.e. reaching 90% 
degeneration in a few days 53. In other PD models, changes in toxin dosage, schedule, route, and 
injection site, are applied to mimic the progressive nature of PD 54. For example, one striatal 
injection of 6-OHDA (20g / 3µL) can induce 30% DA neuronal loss by 14 days, and 50% by 28 
days post-injection 55. Repeated 6-OHDA (100 µg / 4µL) intraventricular administration via an 
implanted cannula also induced progressive (up to 60%) DA neuronal degeneration 56. In the 6-
OHDA model, the DA neurons lack the PD hallmark Lewy bodies, despite exhibiting DA 
neurodegeneration 53. 
Repeated weekly intraperitoneal (i.p.) injections of MPTP (32 mg / kg) can also generate 
a progressive model of PD 57. Lewy body formation was detected in the MPTP model, depending 
on the mode of toxin administration 58. For example, when low MPTP concentrations are 
delivered continuously via an implanted osmotic minipump over 30 days, mice exhibited Lewy-
like aggregates attributed to chronic impairment of the ubiquitin-proteasome pathway. In contrast, 
upon intermittent MPTP i.p. injections, mice lacked ubiquitin and α-synuclein inclusions, 
attributed to rapid recovery of the ubiquitin-proteasome pathway 59. In monkeys, Lewy-like 
structures were detected upon chronic administration of MPTP (reviewed in 60). 
Vulnerability to MPTP varies among species and strains, as systemic administration of 
MPTP results in loss of DA neurons in mice and monkeys, but not in rats 61;62. Rat resistance to 
MPTP toxicity is attributed to high levels of monoamine oxidase (MAO) present in their 
microvessels at the BBB. Since MPTP is lipophilic, it can cross the BBB. In the brain, MPTP 
exerts its neurotoxic effect once it is metabolized by MAO to 1-methyl-4-phenylpyridine 
(MPP+), which is selectively taken up by DA neurons. MPP+ is not lipophilic and if generated 
outside of the brain it poorly crosses the BBB, as in the case of rats due to their high MAO levels 
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at BBB microvessels, (reviewed in 63). The neurotoxic effects of systemically administered 
MPTP in different species and strains, is thus affected by the rate and site of MPTP conversion to 
MPP+ 64.  
New genetic and toxin models are being created to mimic the progressive nature of PD, 
such as in the case of the MitoPark mouse and the use of Beta-sitosterol beta-D-glucoside 
(BSSG), a toxin found in cycad flour. In MitoPark transgenic mice, Tfam, a gene essential for 
mitochondrial DNA maintenance, is selectively inactivated in DA neurons 65. BSSG mixed into 
food pellets is administered to rats to induce PD pathology 66. Further characterization and 
validation of these new progressive PD models are necessary. 
In relation to the etiology of human PD, genetic factors only account for about 10% of 
PD cases 67, and most toxins commonly used in animal models have little to do with human PD 
etiology. There is no rotenone PD related incidence reported, and only 95 paraquat-linked PD 
cases were described to date 58;68. MPTP-induced PD outbreaks were limited to certain 
geographical regions during the 1970s and 1980s. 6-OHDA was first reported in 1968 to deplete 
noradrenaline (NA) and DA in rat brains 58, before its use in PD animal models. 
In addition to genetic and environmental factors, aging is also a major risk factor for PD, 
as most PD cases are reported in people over 60. The normal aging brain exhibits increased 
neuroinflammation 69;70, and post-mortem studies with PD brains confirm that 
neuroinflammation is involved in PD pathology 19;25;27;29 (reviewed in 26;48). The LPS-mediated 
model of PD is often used to address the relationship between neuroinflammation and the 
pathogenesis of PD. LPS is a lipoglycan component of the Gram-negative bacterial outer wall 
and elicits a strong immune reaction in animals. Single LPS systemic administration to adult 
mice causes progressive dopaminergic neuronal loss 71. However, because microglia are present 
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in a variety of brain regions, activation of microglia and the subsequent proinflammatory 
response induced by LPS are not specific to the SN and involve other regions of the brain. To 
overcome this drawback, LPS is also administered intracranially into the SN, striatum or globus 
pallidus. These later LPS models show microglia activation, dopaminergic neuronal loss with no 
damage to GABAergic or serotoninergic neurons, enhanced α-synuclein nitration, increased 
level of proinflammatory cytokines (IL-1β, TNF-α, IL-6 and NO), and motor deficits (reviewed 
in 72). A significant finding is that the LPS-induced pathological changes were more severe in 
middle-aged (16 month old) rats than in young (3 month old) rats, strongly confirming that aging 
is a critical risk factor in the development of PD 73. One of the shortcomings of this model is that 
when injected intracranially, the LPS effect is acute causing nigral DA neuronal loss within 24 
hours and persisting up to 30 days, thus not mimicking the progressive nature of PD pathology 74. 
Despite all of the described limitations, PD animal models underline microglia as 
initiators of PD pathology. For instance, microglia activation precedes neuronal loss in double 
mutant human α-synuclein expressing transgenic mice, 6-OHDA and rotenone models (reviewed 
in 75). PD animal models of MPTP and LPS also report microglia activation (for review see 76). 
The impact of microglia in PD pathology validated in animal models, is in agreement with 
clinical studies of PET-imaging showing that neuroinflammation is elevated in PD patients 77. 
An important mediator of neuroinflammation is the cyclooxygenase (COX) pathway 78, 
which is a major contributor to neurodegeneration in PD 48. Polymorphisms in the cox-2 gene are 
associated with PD 79;80. In addition, involvement of the COX pathway is clearly demonstrated in 
existing genetic and toxin models of PD. Both idiopathic and lrrk2-associated PD patient 
fibroblasts exhibit increases in COX-2 mRNA levels, and this effect is decreased upon lrrk2 
knockdown 81. COX-2 expression is also significantly increased in the striatum of MPTP-
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injected C57BL/6 mice 82, in the midbrain of rotenone-treated Sprague Dawley rats 83, and in the 
striatum of unilateral 6-OHDA-lesioned Wistar rats 84. Together, these findings support that the 
COX pathway has an impact in PD pathology. 
Epidemiological studies with NSAIDs, which are COX inhibitors, support the role of the 
COX pathway in PD. The first compelling epidemiological study showing the PD therapeutic 
benefits of NSAIDs was reported in 2003 from two cohorts of 98,845 women and 44,057 men of 
the Nurses' Health Study and the Health Professional Follow-up studies, respectively 85. Non-
aspirin NSAIDs lowered the risk of PD by 45%, and two-or-more daily tablets of aspirin yielded 
a similar effect 85. In a later study of two cohorts of 98,892 women and 37,305 men, ibuprofen 
(1-2, 3-5 and 6+ tablets per week) was shown to lower the risk for PD by 15%, 60% and 45% 
respectively 49. When other six published studies of NSAIDs use with PD were pooled together, 
ibuprofen users had approximately 30% less risk of developing PD 49.  
In contrast, clinical studies have not replicated the benefit of using NSAIDs to reduce PD 
risk and pathology. There is thus a critical need to investigate the role of the products and factors 
of the prostaglandin pathway downstream from COX, in PD neurodegeneration. To address this 
need, we previously developed a mouse model of neuroinflammation induced by prostaglandin 
J2 (PGJ2) that exhibits PD-like pathology 86;87. Investigating the role played by the downstream 
prostaglandin products of cyclooxygenase pathway may lead to the development of more 
specific and effective strategies to prevent, treat and assess PD pathology. 
1.b. PROSTAGLANDIN J2 AS AN ENDOGENOUS PRODUCT OF THE 
CYCLOOXYGENASE PATHWAY 
Cyclooxygenases are key enzymes in the conversion of arachidonic acid to 
prostaglandins. In many cell types, COX-1 is constitutively expressed under normal 
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physiological conditions and COX-2 is induced upon injury. In contrast to the periphery, COX-2 
is also constitutively expressed in the CNS 88, playing a role in synaptic function and neuro-
vasodilation 89;90. However, physiological imbalances caused by CNS injury lead to up-
regulation of COX-2 expression and activity 91.  The finding that COX-2 is highly up-regulated 
in SNpc in postmortem PD brains 48 indicates that the COX pathway is a major component of the 
neuropathology and progression of PD. 
During neuroinflammation, increased expression of COX-2 occurs not only in neurons 
but also in astrocytes and microglia 92. Many studies support that COX-2 contributes to 
neurodegeneration in PD, and that NSAIDs may be a viable treatment option 49;93-96. However, 
the role played by the prostaglandin products of cyclooxygenases in the neurodegenerative 
process is not clearly defined. The effectiveness of NSAIDs could be compromised because 
these drugs block the generation of all prostaglandin products of cyclooxygenases, including 
those that are neuroprotective and those that are neurotoxic. 
1. b.1. Cyclooxygenase pathway with a focus on PGD2 
Cyclooxygenases catalyze the conversion of arachidonic acid into prostaglandin H2 
(PGH2). Prostaglandin specific synthases, then convert PGH2 into multiple prostaglandins (PGs), 
some being neuroprotective and others neurotoxic 97-99. PGD2 is the most abundant 
prostaglandin in the rodent brain 3;100 and its level increases under pathological conditions such 
as in models of experimental seizures and ischemia 101. Depending on the circumstances, PGD2 
may play pro-inflammatory or anti-inflammatory roles 102. 
PGD2 is synthesized by two types of Prostaglandin D synthases (PGDS): hematopoietic-
PGDS (H-PGDS) and lipocalin-PGDS (L-PGDS). Although these two enzymes catalyze the 
same type of reaction, they differ in their evolutionary origin, amino acid sequence, tertiary 
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structure, and cellular as well as tissue distribution 103;104.  H-PGDS is involved in 
PGD2 synthesis in peripheral immune and inflammatory cells 105. L-PGDS was first discovered 
in the rat brain 106;107 and is predominantly found in the CNS, male genital organs, heart, kidneys 
and lungs 103. In the brain, L-PGDS together with PGD2, promotes the recruitment and 
morphological transformation of microglia and astrocytes during gliosis 108. L-PGDS was also 
identified as a major apoptotic factor in the plasma of Alzheimer's disease (AD) patients 109. 
The effects of PGD2 are mediated via two types of G protein-coupled receptors (GPCRs), 
DP1 and DP2, to which PGD2 binds with similar affinities in the approximate rages of 4 – 17nM 
110;111
. Activation of DP1 and DP2 receptors leads to opposite effects on cAMP production. The 
DP1 receptor is coupled to a Gs-type G protein, therefore its activation leads to increased 
intracellular cAMP as well as neuronal protection 101;112. In contrast, DP2 receptor activation 
leads to Gi-mediated inhibition of cAMP production, increases in intracellular calcium, and 
neuronal cell death (reviewed in 1). Due to their low calcium buffering capacity 6, SNpc neurons 
could be exceptionally vulnerable to the deleterious effects of DP2 activation. 
The major toxic effects of PGD2 are not attributed to its DP receptor activation. Instead, 
they are mediated by PGD2 spontaneous dehydration to the J-series prostaglandins, PGJ2 and its 
metabolites, ∆12-PGJ2 and 15-deoxy-∆12,14-PGJ2 (15d-PGJ2) 113. PGJ2 binds to the DP2 
receptor with an affinity similar to PGD2, but exhibits a much lower affinity for DP1 (reviewed 
in 1). This contrasting binding affinity of PGJ2 to the two DP receptors could be considered one 
of the mechanisms by which PGJ2 induces its neurotoxic effects. PGJ2 derivatives also activate 
PPARγ nuclear receptors in microglia and astrocytes, which mediate their anti-inflammatory 
effects 114;115. Nonetheless, the expression of PPARγ nuclear receptors are much higher in 
neurons than in microglia and astrocytes 116. Additionally, the affinity of prostaglandins for 
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GPCRs such as the DP1 and DP2 receptors is two to three orders of magnitude higher than for 
PPARγ, shown to be at the µM range (reviewed in 117;118). These data suggest that the effect of 
PGJ2 via PPARγ receptors is more likely greater on neurons than on glia. In addition, the 
neuroprotective and anti-inflammatory effects of PGJ2 via PPARγ are more likely to be 
dampened by its neurotoxic effect via DP2 on neurons and proinflammatory effect via DP1 on 
microglia. 
15-hydroxyprostaglandin dehydrogenase (15-PGDH) is a key prostaglandin-degrading 
enzyme that negatively regulates PG levels 119. 15-PGDH is ubiquitously expressed in 
mammalian tissues and can metabolize a variety of PGs, such as PGE1, PGE2, PGF1, PGF2, 
PGI2, and 6-keto-PGF1. Although PGD2 is a poor substrate for 15-PGDH 119, PGD2 is 
converted by 15-PGDH into 15-oxo-PGD2, which gives rise to the inactive form 13,14-dihydro-
15-oxo-PGD2 120. 15-PGDH expression and activity can be stimulated by NSAIDs, but the level 
of stimulation varies with NSAID type and mechanism of action, as well as cell type. The 
mechanisms by which NSAIDs stimulate 15-PGDH are not yet fully established 121;122. 
1.b.2. PGJ2 as an endogenous mediator of inflammation 
Prostaglandins are important regulators of neuroinflammatory pathways. Upon brain 
injury, activated microglia and astrocytes release large quantities of prostaglandins such as 
PGD2, PGE2, and J-series of prostaglandins, as do neurons to a lesser degree (reviewed in 1).  
 PGJ2 is derived from PGD2 (Fig. 1.1A) which is the most abundant prostaglandin in the 
brain and undergoes most upregulation during pathological events (Fig. 1.1D). The half-life of 
PGD2 is estimated to be ~1.1 minutes in the brain, and J2 prostaglandins are formed from the 
highly unstable PGD2 through non-enzymatic spontaneous dehydration. When tested in neuronal 
cultures, among the four prostaglandins PGA1, D2, E2 and J2, PGJ2 was shown to be the most 
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Fig. 1.1. (A) PGJ2 and its metabolites 1. (B) Receptor-dependent actions of PGJ2 2. (C) 
Receptor-independent action of 15d-PGJ2 1. See text for explanation. (D) Concentrations of 
different prostaglandins in brain cortical tissue of young rats (16-18 days postnatal) at 5min 
post resuscitation after being subjected to asphyxia cardiac arrest for 12min to induce brain 
ischemia 3. Prostaglandin levels were measured by UPLC-MS/MS.  
neurotoxic, whereas PGE2 was the least neurotoxic 123.  
 During neuroinflammation, in vivo concentrations of free J-series prostaglandins can rise 
from less than 10nM to approximately 270nM, as detected in the brain of a rat model of stroke 
124
. Extracellularly, PGJ2 exerts its effects by binding to the DP2 receptor (Fig. 1.1B). However, 
PGJ2 can re-enter cells by diffusion across the plasma membrane, or via a prostaglandin 
transporter. Intracellularly, PGJ2 can bind to the nuclear receptor PPARγ, or can bind covalently 
to proteins as discussed below. 
Unlike other prostaglandins, PGJ2 and its metabolites have a cyclopentenone ring with 
reactive α,β-unsaturated carbonyl groups 125. These highly reactive carbonyl groups mediate the 
formation of covalent Michael adducts (Fig. 1.1C) with free sulfhydryls in cysteine residues in 
glutathione and cellular proteins. Due to its ability to form Michael adducts, measurements of 
local cellular and intracellular PGJ2 levels may not reflect its full concentration during 
neuroinflammation. Covalent modification of cysteine residues in proteins by electrophilic 
compounds such as PGJ2 and its metabolites, may induce neuroprotection or neurotoxicity 125. 
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While cysteine residues are components of most proteins, not all cysteine residues are 
susceptible to modification by electrophilic prostaglandins 126. For example, out of hundreds of 
proteins in human embryonic kidney cells (HEK-293) 127, 15d-PGJ2 forms covalent Michael 
adducts with only 10% of proteins that contain reactive thiols, suggesting a high degree of 
specificity 128. In order to understand the full effect and the mechanisms of action of PGJ2 and its 
metabolites, it is essential to identify the target proteins covalently modified by these 
electrophiles. A recent proteomic analysis of human aortic endothelial cells revealed 358 
proteins covalently modified by 15d-PGJ2 129. Moreover, proteomic analysis identified 11 
plasma membrane proteins from rat cortical neurons, as targets of 15d-PGJ2 Michael addition 130. 
These proteins include glycolytic enzymes [pyruvate kinase M1(PKM1), Enolase 1 and 2 and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)], molecular chaperones [heat shock 
protein 8 (Hsp8) and T-complex protein 1 subunit α (TCP1α)], cytoskeletal proteins [Internexin 
α, Tubulin β2b, glial fibrillary acidic protein (GFAP), type I cytoskeletal keratin 20 (CK20), 
Actin β, and F-actin-capping protein subunit α-2 (CapZα2)], and these  neuronal proteins (except 
CK20) and astrocyte-exclusive GFAP are reportedly associated with amyloid plaques and 
neurofibrillary tangles, which are hallmarks of AD 130.  
One of the principal effects of PGJ2 is to impair the ubiquitin/proteasome pathway (UPP) 
by interfering with the 26S proteasome assembly 131-135, and also by inhibiting de-ubiquitinating 
enzymes such as UCH-L1 123;131;136, one of the most abundant neuronal protein 123;135;137. 
Therefore, PGJ2 triggers the accumulation and aggregation of ubiquitinated proteins and induces 
apoptosis (reviewed in 1), both of which are hallmarks of a variety of neurodegenerative 
disorders including PD. 
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Fig. 1.2.  PGJ2 and its 
metabolites are released from 
activated microglia and 
astrocytes during 
neuroinflammation, which 
could transition from acute to 
chronic state via a positive 
feedback loop between PGJ2 
and COX-2. Adopted from  1. 
Finally, PGJ2 up-regulates COX-2 leading to a positive 
feedback loop that could contribute to its chronic long term 
effects 138;139 (Fig. 1.2). Understanding the self-sustaining cycle 
of neuroinflammatory processes involving activated microglia 
and astrocytes is critical to prevent/ameliorate the development 
of neurodegeneration. The potential long term effects of PGJ2 
present a novel view on the role of chronic neuroinflammation 
in PD, induced by products of the COX pathway.  Since PGJ2 
up-regulates the expression of COX-2 138, PGJ2 has potential to 
initiate various deleterious cascades leading to self-sustained 
progressive neurodegeneration. 
Drugs that can slow or reverse PD pathology are not yet 
available, rendering NSAIDs the only approved drugs that can 
decrease the risk and/or delay the onset of PD, potentially by 
preventing cyclooxygenases from synthesizing prostaglandins. However, NSAIDs yielded mixed 
results in clinical trials due to their serious side effects including bleeding and ulcers 140. The 
need for anti-inflammatory drugs with fewer side effects may be met by investigating the effects 
of potentially neurotoxic prostaglandin, downstream of cyclooxygenase. However, there are no 
rodent models that address the potential of prostaglandins to induce PD pathology, other than our 
previously established PGJ2 mouse model 86;87. In this mouse model, nigral/striatal 
microinfusion of PGJ2 into adult (12 week old) FVB male mice led to: (a) a dose-dependent loss 
of DA neurons in the SNpc with little effect on GABAergic interneurons in SNpr; (b) activation 
of astrocytes and microglia; (c) neuronal Lewy-like body formation; and (d) impaired gait and 
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balance similar to PD motor deficits. This PGJ2-induced mouse model can be used to test 
therapeutic strategies that prevent neurotoxicity induced by products of the COX-pathway, 
downstream of the cyclooxygenases. 
1.c. ADVANTAGES OF DEVELOPING A RAT MODEL OF NEUROINFLAMMATION 
THAT DEVELOPS PARKINSONIAN-LIKE PATHOLOGY 
The unclear etiology of PD is a major obstacles and makes it challenging to create animal 
models that precisely resemble PD pathology and the progressive nature of its development 141. 
Moreover, the development of a neuroprotective intervention for PD is hindered by the lack of 
validated biomarkers. Evaluating new therapies in patients at advanced stage of pathology is 
challenging due to the confounding effects of pre-prescribed treatments and difficulty in 
choosing matching control groups. Therefore, identifying biomarkers would improve diagnostic 
certainty, and identification of appropriate patients for clinical trials, and could also be used as an 
objective measure of treatment efficacy 142. These issues emphasize the need for more effective 
preclinical animal models than the ones currently available. The availability of new and 
improved models would advance the understanding of the heterogeneity of PD pathology 
throughout the disease progression and the development of better evaluation means of 
diagnostics and therapeutics. 
So far no definitive biomarkers have been identified for PD. However, since its 
introduction in the 1950s, positron emission tomography (PET) brain scanning has improved 
diagnosis and assessment of treatment for neurological diseases such as PD (reviewed in 143). 
PET can be used to characterize biological and disease processes in vivo by measuring the 
quantitative distribution of imaging agents labeled with positron-emitting nucleotides. Over the 
years, PET imaging resolution has improved and the number of available radiotracers has 
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increased. The importance of animal model research prompted the use of small-animal 
microPET (µPET) systems specifically designed for small animals such as rats and mice. 
In order to provide details of the structures of interest with accurate quantification that are 
comparable to the levels provided by  human studies, µPET requires a system that has a spatial 
resolution that is 15 times greater for mice and 6 times greater for rats than human PET systems  
144
. However, compared to the 5 mm resolution of a typical human PET system, the spatial 
resolution of a commercial µPET scanner is only approximately 1 mm. The 1 mm spatial 
resolution is just enough to meet the requirement for rat imaging, but is not optimal for mouse 
imaging which requires 0.4 mm spatial resolution 144;145. Current capabilities of µPET systems 
do not allow identification of individual cells. Thus, pathological findings from µPET studies at 
the cellular-level need to be supported by immunohistochemistry 146. Nonetheless, µPET has 
significant merit in studying the biological process in a single organism in vivo providing for 
longitudinal observations. 
Besides the size advantage for µPET imaging and surgical procedures, rat models are 
superior to mouse models for human diseases, because rat physiology is easier to monitor and is 
more similar to that of human diseases than mouse physiology. In addition, for neuroscience 
research, rats have an edge over mice because rats are able to perform a wider range of cognitive 
tests, and are less prone to get stressed by handlers 147;148. Additionally, although rats and mice 
have an overall identical brain anatomy, several major important differences in rat brains have 
been reported over the years. These differences include the distribution of a subtype of serotonin 
receptor which is involved in mood regulation, the expression of LRRK2 which is known to be 
linked to PD, and the rate of neurogenesis in the hippocampus (reviewed in 148). 
Based on all of these considerations, we decided to develop a rat model of 
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neuroinflammation by microinjecting PGJ2 into the SNpc to induce PD-like pathology, such as 
motor deficits correlated with progressive DA neuronal loss in the SNpc, activation of microglia 
and astrocytes assessed in vivo with µPET imaging and in vitro by immunohistochemistry, and 
the accumulation of ubiquitinated proteins and α-synuclein containing aggregates. In order to 
address potential mechanisms by which PGJ2 induces toxicity in the rat model of 
neuroinflammation, we characterized (for the first time ever) the distribution and levels of 
downstream factors of the COX pathway: COX-2, L-PGDS, DP2 receptor and 15-PGDH. These 
factors are highly relevant to neuroinflammation in PD as described in detail above.  
The PGJ2 rat model of neuroinflammation that we developed is highly relevant to the 
etiology of PD because PGJ2 is an endogenous product of COX-2, which is highly upregulated 
in PD brains. The PGJ2 rat model exhibits a wide range of pathological and behavioral features 
collectively shown in other established PD animal models which involve COX-2 upregulation. 
The progressive nature of PD-like pathology exhibited in the PGJ2 rat model spans over 8 weeks, 
much longer than ~30 days shown in MPTP and 6-OHDA animal models for PD 54-57, and is 
highly advantageous in exploring potential therapeutics and biomarkers. Investigations into the 
prostaglandin D2/J2 pathway downstream of cyclooxygenases in the PGJ2 rat model could 
discover novel therapeutic targets to protect neurons exposed to chronically activated glia.  
Future studies using the PGJ2-induced rat model for in vivo detection of early stages of 
neuroinflammation with µPET imaging, will provide a means to assess an important aspect of 
neuroinflammation in PD and potentially identify the optimal time window for therapeutic 
intervention. In addition, the newly established rat model can be used to assess the efficacy of 
neuroprotective or neurorestorative therapeutics for PD patients in a non-invasive continuous 
manner.  
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2.1. ABSTRACT 
Prostaglandins are products of the cyclooxygenase (COX) pathway, which is implicated 
in the pathogenesis of Parkinson’s disease (PD). However, limited knowledge is available on the 
roles and mechanisms by which prostaglandins contribute to PD neurodegeneration in vivo. To 
address this gap, we established a rat model of neuroinflammation induced by the highly 
neurotoxic prostaglandin J2 (PGJ2), which is spontaneously derived from PGD2. PGD2 is the 
most abundant prostaglandin in the brain and it increases the most under pathological conditions. 
Unilateral nigral PGJ2-microinfusions in the rats were sufficient to induce progressive PD-like 
pathology. Concomitant with dopaminergic neuronal loss in the SN pars compacta (SNpc), the 
PGJ2-treated rats exhibited progressive microglia and astrocyte activation, and motor deficits. 
We investigated the impact of PGJ2-treatment on key factors of the prostaglandin D2/J2 
pathway, including: COX-2, lipocalin-type PGD2 synthase (L-PGDS), PGD2/J2 receptor 2 
(DP2), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a PG-inactivating enzyme. In 
SNpc DA neurons, COX-2, L-PGDS, and 15-PGDH levels increased significantly in PGJ2-
treated rats compared to controls. DA neuronal DP2 receptor levels were similar in all rat groups. 
In microglia, COX-2 and L-PGDS increased upon PGJ2-treatment. Microglial DP2 receptors 
were almost absent in control and PGJ2-treated rats, while 15-PGDH levels were comparable in 
all rat groups. We also detected 15-PGDH in SNpc oligodendrocytes. Notably, ibuprofen 
prevented most of the PGJ2-induced PD-like pathology. Overall, our studies establish that the 
PGJ2-induced rat model mimics, to a certain extent and in a short time frame, the progressive 
nature of PD pathology. Moreover, we address, to our knowledge for the first time, the potential 
of targeting factors downstream of cyclooxygenases to improve treatment outcomes. Based on 
our data we propose that DP2 receptor antagonists and L-PGDS inhibitors are novel putative 
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therapeutics that may bypass the adverse side effects of cyclooxygenase inhibitors, and 
ultimately diminish neuroinflammation-mediated neurodegeneration in PD. 
2.2. INTRODUCTION 
Neuroinflammation is a defense response activated upon CNS injury to acutely initiate 
repair mechanisms, while chronic neuroinflammation can exacerbate, spread and prolong CNS 
injury. It is well accepted that chronic neuroinflammation plays a central role in Parkinson 
disease (PD) 149-154. Critical to neuroinflammation is cyclooxygenase-2 (COX-2), which is highly 
induced in PD and negatively affects neuronal function 48;112;155-157.  
As far as we know, there are no models of PD that utilize endogenous products of 
cyclooxygenases to mimic the pathology and motor deficits of PD 153, besides our recent studies 
with mice 86;87. PGD2 is the most abundant prostaglandin in the brain 3;100;102;158, and the one that 
rises the most under pathological conditions 101. PGD2 is highly unstable (estimated brain half-
life of 1.1 min), leading to spontaneous non-enzymatic formation of PGJ2 113. Our rationale for 
using PGJ2 to establish a rat model of neuroinflammation that develops progressive 
parkinsonian-like pathology, is that PGJ2 is highly neurotoxic compared to PGD2 and PGE2 123. 
In contrast to PGD2 and PGE2, PGJ2 and its metabolite 15d-PGJ2 bind covalently to proteins 
through their α,β-unsaturated carbonyl groups 159. In addition, the J2 prostaglandins are uptaken 
by cells via a carrier-mediated active transport, ending up in the cytoplasm and nucleus 160. This 
endocytic transport is unique to J2 prostaglandins, as it does not apply to PGD2 and E2 160.  
In rodents, the brain levels of PGJ2 are highly induced upon stroke (cerebral ischemia) 
3;124;136
 and traumatic brain injury (TBI) 161;162, reaching concentrations 3 that are known to be 
neurotoxic. Moreover, both stroke and TBI increase the long-term risk for PD 163-167. We recently 
showed that PGJ2 induces PD-like neuropathology in mice 86;87. Unilateral nigral microinfusion 
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of PGJ2 into mice induced a selective loss of dopaminergic (DA) neurons in the substantia nigra 
pars compacta (SNpc), while sparing DA neurons in the ventral tegmental area (VTA) and 
GABAergic neurons in the SN pars reticulata (SNpr). Furthermore, PGJ2 microinfusions caused 
the accumulation of ubiquitinated proteins, microglia activation, as well as motor deficits in the 
mice.  
Rat models offer many advantages over mouse models for human disease 147. Rats share 
90% of their genome with humans, and most currently identified disease-linked human genes 
have equivalent ones within the rat genome 168. Compared to the mouse, rat physiology is easier 
to monitor and closer to the human condition, and rats are more intelligent and capable of 
learning a broader variety of tasks 147. Rats are also larger than mice and thus better suited for 
surgeries, and for use in the small-animal PET system (µPET) in preclinical research and drug 
development, which requires high spatial resolution. This is particularly important in the CNS. 
Based on all of these advantages, we focused our studies on developing a PGJ2-induced rat 
model of neuroinflammation relevant to PD.  
As limited information is available on the role and mechanisms by which prostaglandins 
contribute to neurodegeneration in vivo, we investigated the impact of PGJ2 microinfusions on 
key factors of the prostaglandin D2/J2 pathway, including: COX-2, lipocalin-type PGD synthase 
(L-PGDS), PGD2/J2 receptor 2 (DP2), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH), 
a PG-inactivating enzyme. L-PGDS converts PGH2 to PGD2, and is found in the CNS, male 
genital organs, heart, kidneys and lungs 103. The DP2 receptor is a Gi protein coupled receptor 
that binds PGD2 and J2 with similar affinities, resulting in a decrease in cAMP and an increase 
in calcium levels 169. 15-PGDH is ubiquitously distributed in mammalian tissues, and is the key 
enzyme negatively regulating prostaglandin levels 170. We compared the levels and cell-type 
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distribution (DA neurons versus microglia) of these four key factors of the prostaglandin 
pathway in control (DMSO) and PGJ2-treated rats, in an effort to identify potential new targets 
for therapeutic intervention downstream from cyclooxygenases, thus with fewer side effects. 
In neurons, PGJ2 upregulates COX-2 138 potentially establishing a positive feedback loop 
between PGJ2 and COX-2 that could promote the transition from acute to chronic 
neuroinflammation. To investigate whether inhibiting cyclooxygenases diminishes the 
progressive PD-like pathology induced by PGJ2, we administered ibuprofen orally with food, to 
control (DMSO) and PGJ2-treated rats. Ibuprofen is a non-steroidal anti-inflammatory drug 
(NSAID) that inhibits COX-1 and COX-2, thus reducing the synthesis of all prostaglandins 150;154. 
Epidemiological studies support an inverse relation between the use of ibuprofen and the risk of 
developing PD 49;171, with the risk reduction being as much as 50% 172. However, there are 
conflicting results 5;172. Clinical studies with NSAIDs have not showed a similar trend 5;173. A 
better understanding of the shared and diverse mechanism of action of NSAIDs, including 
cyclooxygenase inhibition and decreased prostaglandin production, is required to more 
effectively modulate the neurotoxic outcomes of neuroinflammation with fewer side effects 5. 
In summary, our newly developed PGJ2-induced rat model of neuroinflammation 
exhibits progressive parkinsonian-like pathology that persists over a long period of time, and that 
can be diminished by administration of an NSAID such as ibuprofen. Based on our new findings, 
we propose that this pre-clinical rat model induced by PGJ2 is highly valuable to identify 
biomarkers and optimize therapeutics, such as DP2 receptor antagonists and L-PGDS inhibitors, 
which prevent or delay the progression of PD associated with neuroinflammation.  
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2.3. MATERIALS AND METHODS 
Our study followed the strict recommendations in the Guide for the Care and Use of 
Laboratory Animals of the National Institutes of Health (NIH). Our protocol was approved by 
the Hunter College, CUNY Institutional Animal Care and Use Committee. Surgeries were 
carried-out under isoflurane anesthesia, and we made all efforts to minimize animal suffering.  
2.3.1. Reagents and antibodies - PGJ2 (cat. # 18500) and ibuprofen (cat. # 70280) from 
Cayman Chemical (Ann Arbor, MI). PGJ2 (33.4 µg / injection) was diluted in DMSO and then 
further diluted in PBS to a final DMSO concentration of 17% for PGJ2 microinfusions. The 
PGJ2 solutions were freshly prepared and stored for a maximum of 2h at 4°C and in the dark. A 
17% DMSO/PBS was microinfused as the vehicle control. Primary antibodies: dopaminergic 
neurons [TH, tyrosine hydroxylase, 1:1000, cat.# MAB318 (mouse), Millipore (Billerica, MA) 
and cat.# Ab6211 (rabbit), Abcam (Cambridge, MA)]; microglia [Iba1,  1:500, cat.# 019-19741 
(rabbit), Wako (Richmond, VA) and 1:1000, cat.# ab139590 (chicken), Abcam]; astrocytes 
[GFAP, 1:1000, cat.# AB5541 (chicken), Millipore]; oligodendrocytes [GST-pi, 1:200, cat.# 
ab53943 (goat), Abcam]; polyubiquitinated proteins [Ub, 1:200, cat.# BML-PW8805 (mouse), 
Enzo Life Sciences (Farmingdale, NY)]; phosphoS129 α-synuclein [pS129 α-syn, 1:200, cat.# 
p1571-129, PhosphoSolutions (Columbia, MD)]; cyclooxygenase-2 [COX-2, 1:250, cat.# 
160106 (mouse), Cayman Chemical (Ann Arbor, MI)]; prostaglandin D synthase [L-PGDS, 
1:200, cat.# ab182141 (rabbit), Abcam]; prostaglandin D2 receptor [DP2, 1:1000, cat.# PA5-
20332 (rabbit), ThermoFisher (Waltham, MA)]; 15-Hydroxyprostaglandin dehydrogenase [15-
PGDH, 1:500, cat.# NB200-179, Novus (Littleton, CO)]. Secondary antibodies – Alexa Fluor 
568 (1:250, cat.# A11036, rabbit and cat.# A11031, mouse), Alexa Fluor 488 (1:250, cat.# 
A11039, chicken) and Alexa Fluor 350 (1:250, cat.# A10039, rabbit and cat.# A10035, mouse) 
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from Life Technologies (Carlsbad, CA). Vectashield mounting medium (cat# H-1000, Vector 
Laboratories, Burlingame, CA). 
2.3.2. Rats - Sixteen-week old Sprague Dawley male rats (N = 37; body weight: 376 g - 533 g) 
were obtained from Taconic Biosciences (Hudson, NY) and Envigo (Frederick, MD). Rats were 
singly housed on a 12-h light/dark cycle, maintained at 23oC and 50-70% humidity, with food 
and water available ad libitum. Rats were allowed to acclimate for one week before the baseline 
behavior assessment, and were 18 weeks old at the time of the first injection.  
2.3.3. Surgery and microinfusions - We followed the same procedures for the rats as described 
in our previous study with mice 87. Rats received unilateral (right side) injections of vehicle 
(DMSO) or PGJ2 into the SN. Briefly, at 18 weeks of age, rats were anesthetized by isoflurane 
inhalation (induction 2.5%-3.5%, maintenance 2.5%) administered in 100% oxygen and placed 
into a stereotaxic frame (Model 51730D, Stoelting Co., Wood Dale, IL) fitted with a gas 
anesthesia mask (Model 906, David Kopf Instruments). A burr hole was drilled in the skull at 
coordinates for the SNpc 174: anterior-posterior (AP) = -5.6mm; medial-lateral (ML) = +2.0mm; 
and dorsal-ventral (DV) = -8.0mm relative to the bregma. All injections were administered to the 
right SN, while the contralateral (left) side served as an internal control. A two µL microinjection 
Hamilton syringe (7002 KH) with a 25-gauge needle was slowly inserted into the brain and left 
in place for two minutes. Thereafter, two µL of solution was infused at an injection rate of 0.2 
µL/minute (Quintessential stereotaxic injector, Model 53311, Stoelting Co.). The needle was left 
in place an additional three minutes to ensure total diffusion of the solution. Following injection, 
the needle was slowly removed and the incision was closed with monofilament absorbable 
sutures (cat. # 038729; Henry Schein, Melville, NY). After surgery, rats were removed from the 
stereotaxic frame and administered a subcutaneous injection of one cc Lactated Ringer’s solution, 
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given wet palatable rodent chow, and kept in a warm place to recover. Subsequent injections to 
the SN were administered via the same drill hole established during the first surgical procedure.  
2.3.4. Ibuprofen administration – Ibuprofen can be administered to rats twice daily for up to 80 
days without adverse secondary side effects 175. In our experiments, rats were fed ibuprofen 
fortified chow (ibuprofen: ~40mg/kg body weight) ad libitum chronically starting immediately 
after the first PGJ2 treatment. Ibuprofen was added to Purina 5001 Rodent Chow (800 ppm, 
Research Diets, Inc., New Brunswick, NJ). Individual intake of ibuprofen was measured by daily 
weighing of the given and leftover chows per animal.  
2.3.5. Groups - Rats were randomly assigned to 8 groups receiving the following microinfusions 
(Fig. 2.1): (1) four DMSO alone, sacrificed 4 weeks after the last injection; (2) four DMSO/PGJ2, 
sacrificed 4 weeks after the last injection; (3) two DMSO alone, sacrificed 4 weeks after the last 
injection; (4) two DMSO/PGJ2, sacrificed 4 weeks after the last injection; (5) two DMSO alone, 
sacrificed 8 weeks after the last injection;   (6) two DMSO/PGJ2, sacrificed 8 weeks after the last 
injection; (7) two DMSO and fed ibuprofen, sacrificed 4 weeks after the last injection; (8) two 
DMSO/PGJ2 and fed ibuprofen, sacrificed 4 weeks after the last injection. Rats in each group 
received two or four unilateral DMSO or PGJ2 injections (once/week for two or four consecutive 
weeks), starting at the age of 18 weeks. 
2.3.6. Behavior - Rats were tested for parkinsonian-like behavior four and eight weeks after their 
last injection (Fig. 2.1). We used the cylinder behavioral test that assesses spontaneous activity 
and limb use asymmetry in a novel environment. This is a sensitive behavioral test used to detect 
unilateral damage to the nigrostriatal pathway 176. An additional advantage of the cylinder test is 
that inter-rater reliability is very high (r > 0.95) even with relatively inexperienced raters 176;177.  
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Rats were placed in a transparent cylinder (11 inches in diameter and 18 inches in height) 
and video-recorded for 5 – 10 minutes depending on the activity level. A mirror was placed at an 
angle underneath the raised cylinder to allow the view of the back wall and the bottom of the 
cylinder. To determine the extent of asymmetry, the use of the left and right forelimbs were 
counted during the wall movements after a rear, and during the landings as described in 176.  
Forelimb use asymmetry is determined by the preference towards the non-impaired 
forelimb for weight shifting movements during spontaneous vertical exploration. These 
movements along the wall and landings after a rear, were separately recorded and then averaged 
for total asymmetry, to correct for variability as described in 176;177. Each cylinder video was 
scored by two raters blind to the experimental group to further reduce the variability. Their 
scores were averaged and statistically analyzed.   
Rodents display innate limb preference correlated to endogenous nigrostriatal DA 
imbalance 178. Thus, the effect of the unilateral surgery on the behavior was measured as percent 
(%) change of the forelimb use asymmetry post-surgery, compared to the baseline behavior pre-
surgery.  
2.3.7. Immunohistochemistry – After the behavior analyses, rats were anesthetized (i.p.) with 
ketamine (100 mg/kg) and xylazine (5 mg/kg), and transcardially perfused with 4% 
paraformaldehyde in PBS. The rat brains were removed, post-fixed overnight at 4°C, followed 
by cryoprotection (30% sucrose/PBS at 4°C). Brains were sectioned in the coronal plane using a 
freezing microtome at a thickness of 30µm, and sections were collected serially along the 
rostrocaudal axis of the substantia nigra pars compacta (SNpc) [between -4.56mm and -6.36mm 
for the SNpc; coordinates relative to bregma, as in 174]. Tissue series (eight series for the SNpc) 
were stored at 4°C in cryoprotectant (30% glycerol and ethylene glycol in PBS) until use. Each 
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series was processed as free floating sections for immunohistochemical analyses as described in 
86
. At the end, sections were mounted on gelatin-subbed glass slides with Vectashield. Sections 
were viewed under a wide-field fluorescence microscope (Zeiss AxioImager) using a Zeiss 
AxioCam MRm Rev. 3 camera connected to a motorized stage, the software AxioVision 4 
module MosaiX was used to capture whole SN region mosaics (10x magnification). 
Exposure time for each channel was kept consistent between sections. For each captured 
image, ZVI files were loaded onto Image J (NIH, Bethesda, MD) and converted to .tif files for 
use in optical density and co-localization analyses.  Each channel was analyzed to a threshold 
between predetermined standard deviations from the mean intensity per antibody of interest to 
isolate the positive signal from each image 179. Pixel areas meeting threshold intensity criteria 
were measured in delineated SN regions.  
The SNpc was delineated based on TH+ staining at 10× magnification while carefully 
excluding cells within the ventral tegmental area (VTA).  
For optical density (O.D.) analysis, three tissue sections per treatment group were used 
for quantification. Nonspecific background density was corrected using ImageJ rolling-ball 
method 180. Data was expressed as O. D. ratio from the ipsilateral SNpc over the contralateral. 
2.3.8. Stereology - Unbiased stereology analysis was conducted by scorers blind to the 
experimental treatments as described in 87. Total number of TH+ and Iba1+ cells were obtained 
with the Zeiss AxioVision Release 4.8.2 Software unbiased stereology programming (Carl Zeiss 
Group, Jena, Germany). The outline of the SNpc delineated by TH+ staining 181 was obtained at 
low (10x) magnification. Within the delineated SNpc area, depending on the anterior-posterior 
position of the coronal section, 5-11 sites were sampled with the optical fractionator probe. For 
each brain, six SNpc sections spaced 240 µm apart were used for the analyses. Cells were 
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counted at 40× magnification along the AP axis, and at predetermined intervals [x-step = 230 
µm; y-step =170 µm; 39,100 µm2; frame associated area (grid size): horizontal =226.057 µm, 
vertical = 168.380 µm; 38063.478 µm2]. The z-depth was set at 20 µm to allow a 5 µm guard on 
the top and bottom surface of each section to avoid error in case of tissue damage.  Estimated 
cell numbers in the whole SNpc were used for group comparison. Dopaminergic (DA) cell 
counts from the intact SNpc were similar to a previous report 182.  Care was taken to ensure that 
cells within the ventral tegmental area (VTA) were excluded from SN quantification.   
2.3.9. Statistical analyses - All data are expressed as the mean ± SEM. Statistical analyses were 
performed with GraphPad Prism 6 (GraphPad Software, San Diego, CA). A p-value < 0.05 was 
considered statistically significant. For group comparisons, we performed one way analysis of 
variance (ANOVA) followed by post hoc Tukey’s. One way Student's T-test was used to 
compare means between two groups. Correlations between two variables were evaluated by 
linear regression calculating the Pearson correlation coefficients.  
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(18 weeks of age at the time of 1st injection)
PGJ2 [33.4 µg in (DMSO/PBS, 17 %)] or control (DMSO/PBS, 17 %) 
Unilateral injections (2 µL) into right SNpc
Baseline Behavior
(Cylinder test)
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PGJ2 or
DMSO (Control)
4X Injections: 
PGJ2 or
DMSO (Control)
Behavior 
(n = 4 / gp)
IHC (n = 3 / gp)
Behavior 
(n = 4-5 / gp)
IHC (n = 3 / gp)
Behavior 
(n = 5-7 / gp)
IHC (n = 3 / gp)
Behavior 
(n = 4 / gp)
IHC (n = 3 / gp)
+ 4 weeks + 4 weeks
+ IBP
+ 4 weeks+ 8 weeks
  
Fig. 2.1. Schematic representation of the experimental design for the rat PGJ2-treatment. 
Eighteen-week-old male Sprague Dawley male rats were microinjected into the right 
substantia nigra pars compacta (SNpc) as shown. Rats received two or four microinfusions of 
either DMSO (control; 17% in PBS) or PGJ2 (33.4 µg) in 2 µL DMSO/PBS at weekly intervals. 
Ibuprofen (IBP) treated rats were fed IBP-mixed chow (800 ppm, ~40 mg / kg body weight) 
starting the day after the first microinfusion and ending five weeks later. For all rats motor 
behavior was assessed before the first injection and four weeks or eight weeks after the last 
injection. Following post-injection behavioral assessment, rats were perfused intracardially 
and the brains were removed for immunohistochemical analyses. n = number of rats per group 
(gp). 
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2.4. RESULTS 
2.4.1. PGJ2 induces progressive dopaminergic neuronal loss in the rat SNpc  
Following our recently established PGJ2-induced mouse model of PD-like pathology 86;87, 
we investigated in vivo the progressive effects of subchronic inflammation in rats. For this 
purpose, rats were administered unilateral (right side) injections of 33.4 µg / 2 µL PGJ2 to the 
SNpc for two or four weeks (once per week) as depicted in Fig. 2.1. Following behavioral 
analysis, the rats were sacrificed four or eight weeks post the last injection, and their brains 
analyzed by immunohistochemistry.  
To assess dopaminergic specific neuronal damage, we performed immunohistochemical 
(IHC) staining for tyrosine hydroxylase (TH). We used the unbiased optical fractionator 
stereological method and compared the ratio between the numbers of TH+ cells in the ipsilateral 
SNpc over that in the contralateral side for each rat. 
Rats treated with four PGJ2-microinfusions and sacrificed four weeks following the last 
injection, displayed intense (74%) dopaminergic (DA) neuronal loss in the ipsilateral SNpc (Fig 
2A, second panel, and 2B, right panel), compared to DMSO-treated rats. We thus decided to 
reduce the number of injections to two, with the hope of detecting progressive DA neuronal loss. 
Indeed, DA neuronal loss was significantly less upon two than four PGJ2 injections (Fig. 2.2A, 
third and fourth panels, and 2B, right panel). Moreover, DA neuronal loss was progressive, as it 
significantly [p = 0.005] intensified eight weeks compared to four weeks post-injection. 
Compared to DMSO-treatment, DA neuronal loss was 32% and 20% respectively, eight and four 
weeks following PGJ2-treatment. The contralateral SNpc served as the uninjected control for 
each rat, and no significant differences were detected among groups (Fig. 2.2A and B, left panel).  
The DA neurons in the VTA were less affected than those in the SNpc (Fig. 2.2C). 
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Immunostaining for neuron-specific nuclear protein (NeuN) decreased significantly in the SNpc, 
following PGJ2 administration [p = 0.002], thus corroborating that the loss in TH 
immunostaining was due to the degeneration of DA neurons and not to TH depletion (Fig. 2.2D, 
left panel). The decrease in NeuN+ immunoreactivity in the VTA and SNpr was either non-
significant or less than in the SNpc (Fig. 2.2D, right panel). 
2.4.2. PGJ2-treated rats develop parkinsonian-like motor deficits in a progressive manner 
Clinically, PD is characterized by the development of motor deficits caused by the loss of 
dopamine in the SNpc 183-185. To determine the effect of PGJ2 treatment on motor performance, 
we measured the forelimb use asymmetry with the cylinder test which is considered a sensitive 
measure of the degree of unilateral nigrostriatal damage 186. Unilateral injections into the right 
SN should cause forelimb impairment in the contralateral (left) side, and encourage the use of the 
ipsilateral, right-forelimb, thus reflecting a change in nigrostriatal DA. For each animal, the 
percent (%) change in asymmetry between pre (baseline) and post-injection was calculated. The 
mean ± SEM for each treatment group was used for the statistical analysis.  
Weekly PGJ2-microinfusions induced a gradual and significant bias toward use of the 
ipsilateral over the contralateral forelimb when compared to the DMSO controls (Fig. 2.3A). The 
Pearson correlation coefficient indicates a significant negative correlation between ipsilateral 
forelimb use and the number of ipsilateral TH+ cells in the SNpc in the PGJ2-treated rats (r2 = 
0.6, p = 0.007; Fig. 2.3B, right panel). Such correlation was absent for the DMSO-treated rats (r2 
= 0.047, p = 0.287; Fig. 2.3B, left panel). 
These behavioral assessments together with the IHC data for the TH+ DA neurons (Fig. 
2.2) strongly support that PGJ2 induces the development of PD-like pathology in a progressive 
manner over the period of eight weeks post-treatment.   
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Fig. 2.2. Progressive dopaminergic neuronal loss in the SNpc upon successive intranigral PGJ2 
microinjections. (A) Representative coronal sections of the ventral midbrain depicting dopaminergic 
neurons. TH-immunoreactivity was strong in the VTA (ventral tegmental area) and SNpc (substantia 
nigra pars compacta, rectangle) of control (DMSO) rats. TH-immunoreactivity decreased in the 
ipsilateral SNpc of rats receiving two (2X) or four (4X) PGJ2 injections. Dopaminergic neurons in the 
VTA were less affected. Scale bar = 500 µm. (B) The extent of PGJ2-induced damage was assessed 
by calculating the total number of TH+ neurons (mean ±SEM) in the SNpc using unbiased stereology 
as described in Materials and Methods. No significant differences in TH+ neurons were observed in 
the contralateral SNpc of the different groups of rats. TH+-immunoreactivity decreased in a gradual 
manner in the ipsilateral SNpc of rats receiving two (2X) or four (4X) PGJ2 injections and at four 
weeks or eight weeks post-injections of two (2X) PGJ2. (C) PGJ2-induced damage in the VTA was 
measured by TH+ area (mean ±SEM). Dopaminergic neurons in the VTA were less affected than in 
the SNpc. (D) Neuronal loss in the SNpc, VTA and SNpr were compared by NeuN+ area (mean 
±SEM). NeuN-immunoreactivity decreased significantly in the SNpc, but less in the VTA and not 
significantly in the SNpr of PGJ2-injected rats compared to controls (DMSO-treated). Black circles, 
control, DMSO-treated rats; red circles, PGJ2-treated rats. Statistical significance was estimated with 
One-way ANOVA (B, left) and the Student's T-test (B, right, C and D) to compare DMSO and PGJ2-
treated groups and between two PGJ2-treated groups. The p values in red indicate statistical 
significant (<0.05) difference from DMSO-injected rats. N = 3 rats per group. 
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Fig. 2.3. Correlation between behavioral deficits and dopaminergic (TH+) neuronal loss in the SNpc 
induced by successive PGJ2 microinfusions. (A) All groups of rats treated with PGJ2 (shades of red 
circles) exhibited behavioral deficits. When compared to DMSO-treated rats (white, gray and black 
circles), those treated with 2X and 4X PGJ2 significantly increased usage of the ipsilateral forelimb 
as assessed by the cylinder test (see Materials and Methods). Statistical significance was estimated 
with the Student's T-test to compare DMSO and PGJ2-treated groups and between two PGJ2-
treated groups. The p values in red indicate the values that are significantly (<0.05) different from 
DMSO-injected rats. N =4 to 5 rats per group. (B) In the PGJ2-treated but not in the control (DMSO) 
rats, dopaminergic neuronal loss (TH+) in the ipsilateral SNpc (x-axis) inversely correlates with 
forelimb usage asymmetry (y-axis). 
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2.4.3. PGJ2-treatment alters the morphological/functional properties of activated microglia 
in the rat SNpc, but does not change microglia total numbers in the same area  
We analyzed the number of microglia in DMSO and PGJ2-treated rats. The intact 
contralateral SN served as the control for each rat. We thus evaluated and compared the activated 
microglia numbers for each rat, as a ratio between ipsilateral over contralateral sides.  
Due to the surgical procedure, SN injections of DMSO alone increased microglia activity 
as assessed by Iba1 immunostaining. Compared to DMSO-treatment, PGJ2 did not significantly 
(p>0.07) change the overall numbers of activated microglia, (Fig. 2.4A and B).   
Activated microglia exhibit a remarkable variety of morphologies that can be associated 
with their particular functions 187. Using binary images of individual microglia silhouettes, we 
distributed activated microglia into three different groups according to their form factor (FF) 
value (Fig. 2.4C), which is defined as 4pi X area / perimeter2 188. Each of the three microglia 
groups is defined as follows 187: Ramified, FF: 0 to 0.5; actively engaged in neuronal 
maintenance providing neurotrophic factors. Reactive, FF: > 0.5 to 0.7; responsive to CNS injury. 
Amoeboid, FF > 0.7 to 1; cell body is amorphous with pseudopodia.  
Based on the FF values, we observed a significant rise in reactive (p=0.026) and 
amoeboid (p=0.005) microglia in PGJ2-treated rats compared to the DMSO-treated ones (Fig. 
2.4D). The rise in reactive and amoeboid microglia was only detected in rats treated with two 
PGJ2 injections and sacrificed four weeks post-injection (Fig. 2.4D). The microglia rise was not 
apparent in the PGJ2-treated rats eight weeks post-injection. The plotted values represent the 
ratio between ipsilateral over contralateral sides for each rat, normalized to the ramified 
microglia, which are the ones associated with normal physiological function.  
  
39 
 
 
  
Fig. 2.4. Successive PGJ2 microinfusions induce microglia morphological and functional changes 
detected post-mortem. (A) TH (blue, dopaminergic) and Iba1 (red, microglia) immunostaining shows a 
gradual loss of dopaminergic neurons and gain of activated microglia in the ipsilateral SNpc. Scale bar 
= 50 µm. (B) The overall numbers of microglia in the ipsilateral SNpc did not significantly change 
between DMSO (control) and PGJ2–treated rats. (C) Microglia morphologic changes represented by 
the form factor (FF) calculated as 4pi X area / perimeter2. (D) The number of reactive and amoeboid 
microglia significantly increased in the ipsilateral SNpc of rats receiving two (2X) PGJ2 injections at 
four weeks but not at eight weeks post-injections, compared to controls (DMSO-treated). Values on 
the y-axis represent the ratios between the ipsilateral SNpc over the contralateral, normalized to the 
number of ramified microglia. Black circles, control, DMSO-treated rats; red circles, PGJ2-treated rats. 
Statistical significance was estimated with the Student's T-test to compare DMSO and PGJ2-treated 
groups and between two PGJ2-treated groups. The p values in red indicate significant (p<0.05) 
difference from DMSO-injected rats. N = 3 rats per group.  
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2.4.4. PGJ2-treatment increases the astrocyte reactivity in the rat SNpc 
Astrocytes in the brain become reactive under pathological conditions, including in 
neurodegenerative diseases 189. Under these conditions, reactive astrocytes overexpress GFAP, 
and undergo morphological changes (hypertrophy and process remodeling) 189.  
Our studies demonstrate that, compared to DMSO, rats that received two PGJ2 
microinjections exhibited, in the SNpc, a significant (p=0.049) increase in the reactive astrocytes 
eight weeks, post-injections (Fig. 2.5A and B). The reactive astrocytes in the other groups of 
PGJ2-treated rats (2X, 4wks, p=0.152; 4X, 4wks, p=0.179) was non-significantly different from 
controls. 
  
41 
 
 
Fig. 2.5. Successive PGJ2 microinfusions induce sustained astrocyte reactivity. (A) TH (blue, 
dopaminergic) and glial fibrillary acidic protein (GFAP, green, reactive astrocytes) immunostaining 
shows a gradual loss of dopaminergic neurons concurring with astrocyte reactivity in the ipsilateral 
SNpc. Scale bar = 50 µm. (B) PGJ2-treated rats show significantly increased astrocyte reactivity in the 
ipsilateral side of the SNpc compared to controls (DMSO-treated) at eight weeks after two (2X) 
injections. Values on the y-axis represent the ratios between the ipsilateral SNpc over the 
contralateral. Black circles, control, DMSO-treated rats; red circles, PGJ2-treated rats. Statistical 
significance was estimated with the Student's T-test to compare DMSO and PGJ2-treated groups and 
between two PGJ2-treated groups. The p value in red indicates significant (p<0.05) difference from 
DMSO-injected rats. N = 3 rats per group. 
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2.4.5. Detection of intraneuronal aggregate-like inclusions of ubiquitinated proteins and 
phosphorylated (pS129) α-synuclein in SNpc DA neurons of rats treated with PGJ2  
The accumulation of proteinaceous intraneuronal inclusions known as Lewy bodies in 
SNpc DA neurons is one of the hallmarks of PD 190. These inclusions contain ubiquitinated 
proteins 191 as well as α-synuclein phosphorylated at S129 (pS129 α-syn) 20. We addressed this 
aspect of PD (Fig. 2.6A for ubiquitinated proteins, and 6B for pS129 α-syn, both quantified in 
6C) by focusing on the TH+ DA neurons of the SNpc. Since our preceding studies already 
demonstrated the progressive nature of the PGJ2-induced rat model, for this analysis and all 
subsequent studies we focused only on four experimental paradigms: rats treated with two 
injections or four injections of DMSO or PGJ2, and sacrificed four weeks post-injections. 
Regardless of the number of PGJ2 injections, there was a shift from a diffuse distribution 
of ubiquitinated proteins and pS129 α-syn detected in TH+ neurons of DMSO-treated rats, to 
more of an aggregated appearance observed in the PGJ2-treated rats (white arrows, Fig. 2.6A 
and B). Moreover, we established that only treatment with four (not two) PGJ2 injections 
induced a significant (p=0.016) rise in the levels of ubiquitinated proteins in the few spared TH+ 
neurons (Fig. 2.6C, left panel). The levels of pS129 α-syn also increased under these conditions, 
almost reaching statistical significance (p=0.089, Fig. 2.6C, right panel).  
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Fig. 2.6. Successive PGJ2 microinfusions induce aggregate-like ubiquitinated proteins (A) and pS129 
α-synuclein deposits (B) in dopaminergic neurons. Immunostaining for ubiquitinated proteins (red in 
A), pS129 α-synuclein (red in B), and TH+ neurons (blue in A and B) at four weeks after two (2X) and 
four (4X) PGJ2 microinjections. Dopaminergic neurons in the SNpc of PGJ2-treated rats exhibit 
aggregate-like ubiquitin conjugates and pS129 α-synuclein neuronal inclusions (white arrows). Scale 
bar = 50 µm. (C) Values on the y-axis represent the optical density (OD) ratios between ipsilateral 
SNpc over the contralateral, normalized to the TH+ signal. Black circles, control, DMSO-treated rats; 
red circles, PGJ2-treated rats. Statistical significance was estimated with the Student's T-test to 
compare DMSO and PGJ2-treated groups. The p value in red indicates significant (p<0.05) difference 
from DMSO-injected rats. N = 3 rats per group. 
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2.4.6. Cell-type distribution and levels of key factors of the prostaglandin D2/J2 pathway  
Up to now our findings corroborated that PGJ2-treated rats develop PD-like pathology in 
a progressive temporal manner. We wanted to take our in vivo investigation one step forward and 
address the impact of PGJ2 on the cell-type distribution and levels of key factors of the 
prostaglandin D2/J2 pathway observed during the four-week window, including COX-2, the 
PGD synthase L-PGDS, the PGD2/J2 receptor DP2, and the prostaglandin dehydrogenase 15-
PGDH (Fig. 2.7). We would like to highlight that the cell-type distribution and levels of these 
four factors has never been investigated under control or stress conditions in the SNpc in relation 
to PD, at least to our knowledge. Like for the ubiquitinated proteins and α-syn studies, we 
focused only on four experimental groups: rats treated with two injections or four injections of 
DMSO or PGJ2, and sacrificed four weeks post-injections. 
We examined by immunocytochemistry, the distribution and levels of these factors in DA 
neurons and microglia in the SNpc by assessing the optical density ratio or co-localization of 
each of these factors with TH or Iba1, respectively. There was no significant difference in the 
levels of these four factors in DA neurons (Fig. 2.7A to D, left) in rats that received 2X PGJ2 
injections (red circles) compared to controls (DMSO-treated, black circles). In contrast, COX-2, 
L-PGDS, and 15-PGDH levels increased significantly in the DA neurons of PGJ2-treated rats 
that received four injections, when compared to controls (Fig. 2.7A, B and D, left). The DP2 
receptor levels were stable in control and PGJ2-treated (4X) rats (Fig. 2.7C). 
In regard to microglia, there was more variation in their responses to PGJ2-treatment. 
Starting with COX-2, we observed a rise in its levels in rats treated twice with PGJ2, but not in 
those treated four times with PGJ2, compared to controls (Fig. 2.7A, right). For L-PGDS, 
significant increases were detected in both groups of PGJ2-treated rats compared to controls (Fig. 
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2.7B, right).  
Notably, DP2 receptors in microglia were almost non-existent or expressed at very low 
levels (Fig. 2.7C, right, and Table 1). When considering ipsilateral and contralateral SNpc 
separately, values representing the number of microglia exhibiting co-localization of the other 
three factors (COX-2, L-PGDS, 15-PGDH) with the microglia marker Iba1, varied between 250 
and 117 (not shown). However, for the DP2 receptor, these values ranged from 50 to 17 (Fig. 2.7, 
Table 1), thus they were 2 to 15 times lower. We suspect that co-localization of DP2/Iba1 
immunostaining is a paradox, and is most likely due to the proximity of a microglia to a DA 
neuron.  
The microglia levels of the prostaglandin dehydrogenase 15-PGDH did not change in any 
of the control or PGJ2-treated groups of rats (Fig. 2.7D, right). We found that this enzyme was 
expressed in another cell type, i.e. oligodendrocytes. The latter were detected in the SNpc of all 
groups of rats with the marker for mature oligodendrocytes, the pi form of glutathione-S-
transferase (GST-Pi, Fig. 2.7E).  
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Fig. 2.7. PGJ2 microinfusions increase COX-2 (A) and L-PGDS (B) levels in dopaminergic neurons 
and microglia. Immunostaining for COX-2 (red in A), L-PGDS (red in B), TH+ neurons (blue in A, B) 
and Iba1+ microglia (green in A, B) at four weeks after two (2X) and four (4X) PGJ2 microinjections. 
Scale bar = 50 µm. (A) COX-2 is significantly increased in dopaminergic neurons from rats receiving 
four (4X) PGJ2 injections than in controls. Co-localization of COX-2 and Iba1 is greater in microglia 
from rats receiving two (2X) PGJ2 injections than in controls. (B) L-PGDS is significantly increased in 
dopaminergic neurons from rats receiving four (4X) PGJ2 injections than in controls. Co-localization of 
L-PGDS and Iba1 is greater in microglia from rats receiving two (2X) and four (4X) PGJ2 injections 
than in controls. Values on the y-axis represent the optical density (OD, normalized to TH, left graphs 
in A and B) or co-localization (normalized to Iba1, right graphs in A and B) ratios between ipsilateral 
SNpc over the contralateral. Black circles, control, DMSO-treated rats; red circles, PGJ2-treated rats. 
Statistical significance was estimated with the Student's T-test to compare DMSO and PGJ2-treated 
groups. The p value in red indicates significant (p<0.05) difference from DMSO-injected rats. N = 3 
rats per group. 
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Fig. 2.7. (cont.) DP2 receptors (C) are predominantly expressed in the SNpc dopaminergic neurons 
and not in microglia. Immunostaining for DP2 (red), TH neurons (blue) and Iba1 microglia (green) at 
four weeks after two (2X) and four (4X) PGJ2 microinjections. Scale bar = 50 µm. (C) DP2 levels 
remain stable in dopaminergic neurons from all treatment groups. Values on the y-axis represent the 
optical density (OD, normalized to TH, left graph in C) or co-localization (normalized to Iba1, right 
graph in C) ratios between ipsilateral SNpc over the contralateral. Black circles, control, DMSO-
treated rats; red circles, PGJ2-treated rats. Statistical significance was estimated with the Student's T-
test to compare DMSO and PGJ2-treated groups. The p value in red indicates significant (p<0.05) 
difference from DMSO-injected rats. Table 2.1 - Low detection levels of DP2 and Iba1 co-localization 
in microglia. N = 3 rats per group.     
 
# of Co - Lo 
DP2 & Iba1
(SNpc) 
2X, 4 weeks 4X, 4 weeks
Control PGJ2 Control PGJ2
Contralateral 29.7 ± 2.9 21.7 ± 2.3 17.3 ± 4.7 30.7 ± 2.7
Ipsilateral 24.3 ± 6.0 20.7 ± 0.3 22.3 ±1.5 50.7 ± 3.9
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Fig. 2.7. (cont.) 15-PGDH (D, E) is detected in dopaminergic neurons, microglia and 
oligodendrocytes in the SNpc. Immunostaining for 15-PGDH (red), TH neurons (D, blue), Iba1 
microglia (D, green), and GST-pi oligodendrocytes (E, green) at four weeks after two (2X) and four 
(4X) PGJ2 microinjections. Scale bar = 50 µm. (D) 15-PGDH expression is increased in dopaminergic 
neurons from rats receiving four (4X) PGJ2 injections, but not in microglia. Values on the y-axis 
represent the optical density (OD, normalized to TH, left graph in D) or co-localization (normalized to 
Iba1, right graph in D) ratios between ipsilateral SNpc over the contralateral. Black circles, control, 
DMSO-treated rats; red circles, PGJ2-treated rats. Statistical significance was estimated with the 
Student's T-test to compare DMSO and PGJ2-treated groups. The p value in red indicates significant 
(p<0.05) difference from DMSO-injected rats. N = 3 rats per group. (E) 15-PGDH is highly expressed 
in SNpc oligodendrocytes from all groups of rats. 
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2.4.7. Ibuprofen prevents most of the PD-like pathology developed in PGJ2-treated rats  
Ibuprofen (IBP) is an NSAID that inhibits COX-1 and COX-2, thus reducing the 
synthesis of all prostaglandins 150;154.  We previously demonstrated that PGJ2 induces COX-2 
up-regulation in neuronal cells 138, potentially establishing a positive feedback loop between 
PGJ2 and COX-2. This positive feedback effect of PGJ2 on COX-2 could promote the transition 
from acute to chronic neuroinflammation and consequently promote progressive PD pathology.  
To determine the contribution of the cyclooxygenase pathway to the PGJ2-induced PD-
like pathology in vivo, we administered IBP to the PGJ2-treated rats. The four groups of rats (2X 
DMSO ± IBP and 2X PGJ2 ± IBP) were analyzed at four weeks post the last PGJ2 treatment, 
with the cylinder test and immunochemistry. Preventive cyclooxygenase inhibition with IBP 
starting the day after the first surgery, ameliorated all PD-like pathology induced by PGJ2, 
except for reactive astrocytes (Fig. 2.8).  
It is clear that IBP reduced DA neuronal loss (Fig. 2.8A and B), as well as reactive and 
amoeboid microglia rise (Fig. 2.8A, C and D) in the SN, and prevented the bias toward use of the 
ipsilateral over the contralateral forelimb (Fig. 2.8F). There was no statistical difference between 
DMSO and PGJ2-treated rats that were fed IBP in relation to these four parameters: numbers of 
TH+ cells (Fig. 2.8B), reactive (Fig. 2.8C) and amoeboid (Fig. 2.8D) microglia, and bias toward 
use of the ipsilateral over the contralateral forelimb (Fig. 2.8F). These results support the 
preventive effects of IBP in terms of PD-like pathology induced by PGJ2, a mediator of 
inflammation. 
In contrast, IBP administration significantly (p=0.05) increased the astrocyte reactivity 
upon PGJ2-treatment, compared to DMSO-treatment (Fig. 2.8A and E). Thus, we show that 
PGJ2-treatment causes sustained astrogliosis, which is not alleviated by the IBP treatment (Fig. 
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2.5 and 2.8A and E). We should note that the role of astrocytes in PD pathology is ambiguous as 
activated astrocytes can produce both pro-inflammatory and anti-inflammatory factors, as well as 
neurotoxic and neurotrophic factors 26. The types of reactive astrocytes that are induced by PGJ2 
± IBP remain to be investigated.  
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Fig. 2.8. Ibuprofen ameliorates the PD-like pathology induced by PGJ2 except for astrocyte activation.         
(A) Ibuprofen treatment starting the day after the first surgery reduces TH+ (blue, dopaminergic) 
neuronal loss and Iba1+ (red, microglia) activation, but not GFAP+ (green, astrocyte) reactivity in the 
SNpc at four weeks (4w) post two (2X) PGJ2-injections. Scale bar = 500 µm. (B) There was no 
statistical difference in TH+ DA neurons between ibuprofen-fed PGJ2-treated rats and ibuprofen-fed 
controls (DMSO-treated). The extent of PGJ2 damage was assessed by calculating the total number 
of TH + neurons (mean ±SEM) in the SNpc using unbiased stereology as described in Materials and 
Methods. (C, D) There was no statistical difference between the number of reactive (C) or amoeboid 
(D) microglia in ibuprofen-fed PGJ2-treated rats and ibuprofen-fed controls (DMSO-treated). (E) 
Astrocyte reactivity is significantly higher in ibuprofen-fed PGJ2-treated rats than in ibuprofen-fed 
controls (DMSO-treated). For A through E, N=3 rats per group. Values on the y-axis represent the 
ratios between the ipsilateral SNpc over the contralateral (in C and D normalized to the number of 
ramified microglia). (F) There was no statistical difference in motor asymmetry between ibuprofen-fed 
PGJ2-treated rats and ibuprofen-fed controls (DMSO-treated). For F, N = 5-7 rats per group. Black 
circles, control, DMSO-treated rats; red circles, PGJ2-treated rats. Statistical significance was 
estimated with the Student's T-test to compare DMSO and PGJ2-treated groups. The p values in red 
indicate significant (p<0.05) difference from DMSO-injected rats.  
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2.5. DISCUSSION 
The frequent failure of potential new treatments in clinical trials suggests that current PD 
models that are used to test them, may not exhibit the critical and/or complete set of PD traits 
experienced in humans. Other types of animal models relevant to PD need to be developed. 
Compelling evidence supports that neuroinflammation, and in particular the cyclooxygenase 
pathway, plays a central role in PD 149-154. However, very few studies address how prostaglandin 
products of cyclooxygenases redirect cellular events to promote neurodegeneration in PD. In the 
current studies, we developed a non-transgenic rat model of neuroinflammation by microinfusing 
PGJ2 unilaterally into the right SNpc. The PGJ2-treated rats displayed DA neuronal loss that 
correlates with motor deficits, as well as gliosis including increases in activated microglia and 
reactive astrocytes. The DA neurons in the SNpc developed aggregate-like ubiquitinated proteins 
and pS129 phosphorylated α-synuclein deposits. We showed that PGJ2 induces the accumulation 
and aggregation of ubiquitinated proteins in rat cortical neurons 192. All of these traits are 
characteristic of human PD-pathology.  
This new PGJ2-induced rat model offers several advantages over other PD models. In the 
first place, we identified elements of the prostaglandin D2/J2 pathway that may be effective 
novel therapeutic targets for PD, downstream of the cyclooxygenase pathway. Based on our data, 
we propose that DP2 receptor antagonists and L-PGDS inhibitors could be new drugs that 
prevent/diminish PD pathology associated with neuroinflammation. DP2 receptors bind PGD2 
and PGJ2 with similar affinities (nanomolar range) 111;193. DP2 receptors are Gi-protein-coupled-
receptors, and their activation downregulates cAMP and increases intracellular calcium levels 
117;194
. We found that DP2 receptors in rats are abundantly expressed in DA neurons of the SNpc, 
while almost lacking in microglia. Thus, PGD2/J2 produced by activated microglia could lead to 
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aggravated DA neuronal damage via DP2 receptor activation. On the other hand, DP2 inhibition 
could ameliorate neuronal dysfunction. In support of neuroprotection accomplished by blocking 
DP2 receptors, DP2 antagonists [CAY10471 and its BAY-u3405 (ramatroban) analog] were 
found to attenuate pain in a peripheral nerve injury rat model 195. In addition, CAY10471 was 
shown to increase survival of rat hippocampal neurons exposed to aluminum 196. In contrast, DP2 
activation was shown to potentiate neuronal injury in rat hippocampal neuronal cultures and 
organotypic slices 101;112. Based on all of these findings, we propose that DP2 antagonists will 
protect DA neurons from the neurotoxic effects of activated microglia in PD, in particular SNpc 
DA neurons, which exhibit low calcium buffering capacity 6. 
In regard to L-PGDS, this enzyme is responsible for most PGD2 synthesis in the brain, 
and is one of the most abundant cerebrospinal fluid (CSF) proteins 103, representing ~3% of total 
CSF proteins 197. We established that PGJ2-treated rats display increased L-PGDS levels, 
suggesting that L-PGDS inhibitors may protect neurons from PGD2/J2-induced PD-pathology. 
The following studies support this premise. Cortical neurons derived from L-PGDS null mice 
exhibited higher cell viability and less accumulation of ubiquitinated proteins in response to 
hypoxic conditions, than those derived from L-PGDS heterozygous mice 113. L-PGDS was also 
identified as the major apoptotic factor in plasma of AD patients 109. In addition, in vivo and in 
vitro studies demonstrated that L-PGDS promotes reactive gliosis related to brain pathology 
108;198
. Alterations in L-PGDS levels in the CSF, were detected in at least 20 idiopathic PD 
patients compared to 100 controls 199. These L-PGDS changes could indicate pathology at the 
cellular level with an impact on PGD2/J2 levels, and also correlate with disease symptoms 199. 
Notably, the L-PGDS specific PET tracer that is a glutathione conjugate of fluorine-18-labeled 
fluorobutyl ethacrynic amide ([18F]FBuEA-GS), is used to assess L-PGDS overexpression in 
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brain tumors 200. Potentially this radiotracer could be useful for PD diagnosis, by providing 
information on changes in L-PGDS levels. Based on all of these studies, we propose that L-
PGDS could be considered a PD biomarker with predictive value 199, and could also be explored 
as a potential drug target for therapeutic intervention in neuroinflammation-driven PD. 
Prostaglandins are unstable, thus act as autocrine or paracrine ligands by exerting their 
effects near their sites of synthesis 201. The enzyme 15-PGDH inactivates prostaglandins in the 
cytoplasm. Therefore, cyclooxygenases and 15-PGDH control prostaglandin cellular levels by 
opposite means. Although 15-PGDH metabolizes neuroprotective as well as neurotoxic 
prostaglandins, higher 15-PGDH levels may be beneficial under conditions where the effects of 
neurotoxic prostaglandins outweigh those of the neuroprotective ones 119. We found that in 
PGJ2-treated rats the levels of 15-PGDH expression in DA neurons seemed equivalent to those 
in control rats. In addition, we detected 15-PGDH in SNpc oligodendrocytes identified with 
GST-Pi, the pi form of glutathione-S-transferase. The presence of 15-PGDH in oligodendrocytes 
may represent a protective mechanism to counteract the increased oligodendrocyte vulnerability 
to excitotoxic death associated with COX-2 up-regulation following, for example, glutamate 
receptor activation 202. 
The second advantage offered by the PGJ2-induced rat model is related to animal models 
that recapitulate the disease phenotype with some degree of fidelity. These animal models should 
be valuable for developing and testing new or repurposed therapeutic agents as well as magnetic 
resonance imaging (MRI) and PET imaging tracers 203. Our current studies show that when 
administered prior to symptom development, ibuprofen, which inhibits COX-1 and COX-2, 
prevented most of the PGJ2-induced PD-like pathology. This finding is important because it 
demonstrates that PGJ2-induced neurodegeneration is mediated in part by activation of the 
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cyclooxygenase pathway that could lead to chronic inflammation. In addition, our data support 
that NSAIDs can be instrumental in preventing DA neurodegeneration associated with 
inflammation. The conflicting epidemiological and clinical results on the potential use of 
NSAIDs to treat PD, could be due to variations in (a) length of treatment (longer in 
epidemiological and shorter in clinical studies), and/or (b) disease stage at the start of treatment 
(pre-pathology in epidemiological and post-pathology in clinical studies), reviewed in 204. The 
PGJ2-induced rat model was also used to test a variety of PET tracers with the major intention of 
assessing in vivo the progression and spreading of neuroinflammation, (manuscript in 
preparation). These latter studies could help establish the optimal timeline for therapeutic 
intervention, to prevent PD pathology linked to neuroinflammation. 
Thirdly, we show that the PGJ2-induced PD-like pathology in the rats developed in a 
progressive temporal manner, as it worsened with time up to 8 weeks post the second PGJ2 
injection, the latest time-point that we analyzed. In animal models, the progressive nature of PD 
neurodegeneration is a hard-to-mimic aspect of this disorder. Toxin and pharmacological 
induced PD models such as 6-OHDA, MPTP, paraquat and rotenone exhibit motor symptoms, 
but they are often related to massive and rapid degeneration of the nigrostriatal pathway 53. A 
similar phenomenon is observed in LPS-mediated models of PD, used to address the link 
between neuroinflammation and PD pathology. LPS administered intracranially into the SN, 
striatum or globus pallidus, causes DA neuronal loss within 24 hours that persists at the same 
level by 30 days, therefore not mimicking the progressive nature of PD pathology 72;74. Single 
systemic administration of LPS causes progressive dopaminergic neuronal loss, although 
microglia activation is not specific to the SN, being detected in a variety of brain regions 71.  
Fourthly, we established that PGJ2 has similar neurotoxic effects in rats and mice, as we 
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previously described for the PGJ2-induced mouse model that displayed comparable PD-like 
pathology 86;87. This is not the case for all drug based PD models, some of which are species-
specific. For example, rats are resistant to MPTP and the MPTP-sensitivity differs widely among 
various strains of mice 52. Moreover, not all PD animal models exhibit DA neuronal degeneration 
and correlated motor deficits, as we detect in the PGJ2-induced rat model. For example, PD 
models based on genetic risk factors such as Parkin, PINK1 and LRRK2 show little or no 
nigrostriatal degeneration and motor symptoms 51. Most PD models, transgenic and non-
transgenic, exhibit some level of neuroinflammation usually detectable early and sometimes even 
pre-symptom development 15;75. It is thus advantageous to address novel targets of 
neuroinflammation, such as we do in the current study. 
In conclusion, the PGJ2-induced rat model of neuroinflammation that we developed 
provides an optimal tool to study the relationship between PGD2/J2-induced chronic 
inflammation and progressive neurodegeneration relevant to PD, to test therapeutics, such as 
DP2 antagonists and L-PGDS inhibitors to prevent/diminish DA neurodegeneration linked to 
neuroinflammation and PD, and to evaluate novel PET tracers to determine the in vivo 
progression of PD-like pathology and establish the optimal temporal window for therapeutic 
intervention.  
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3.1. ABSTRACT 
Upregulation of COX-2 plays a key role in neuroinflammation associated with PD. In 
addition, epidemiological studies indicate that the use of COX inhibiting NSAIDs lowers the risk 
for developing PD. However, NSAIDs are not used as a treatment against PD due to their serious 
side effects. Investigations into the role of prostaglandins and other downstream factors of the 
COX pathway is desirable in order to explore anti-inflammatory treatment options against 
neurodegenerative diseases. 
PGD2, the most abundant prostaglandin in the brain, is upregulated upon brain injuries 
and is converted to the highly neurotoxic PGJ2 by spontaneous dehydration. Chapter 2 discussed 
our newly developed rat model of neuroinflammation induced by PGJ2 that models, in part, the 
progressive nature of PD pathology. DMSO (vehicle) or PGJ2 were microinfused into the right 
side of the SN of adult Sprague Dawley male rats for two weeks (once per week). PGJ2-treated 
rats exhibited motor deficits correlated with progressive dopaminergic neuronal loss. 
Immunohistochemical analyses confirmed the increased activation of microglia and chronically 
reactive astrocytes in the PGJ2-treated rats.  
We assessed in vivo chronic neuroinflammation in the PGJ2-induced rat model. We 
compared µPET imaging with the translocator protein (TSPO) radioligand [11C]PK11195, at 
week four and eight post DMSO and PGJ2-injections. Rats that received two PGJ2-injections 
showed higher [11C]PK11195 uptake compared to controls (DMSO-treated) at both time points, 
demonstrating  chronic glial activation in the PGJ2-injected side of the SN.   
In conclusion, chronic neuroinflammation present in the PGJ2-induced rat model of PD 
can be monitored and assessed in vivo by PET imaging. The PGJ2 rat model may help identify 
and optimize treatments against neurotoxic inflammation to prevent/slow the development and 
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progression of PD. In addition, this novel rat model can aid in the evaluation of novel PET 
radiotracers for neuroinflammation. 
3.2. INTRODUCTION 
Chronic neuroinflammation is associated with neurodegenerative diseases such as PD 
26;149-151;154;205
. However, the mechanisms by which neuroinflammation contributes to the onset 
and progression of PD remain unclear.  
The COX pathway plays an important role in neuroinflammation. The activity of the 
COX pathway increases with normal aging 78 and contributes to neurodegeneration through 
overexpression of COX-2 in the SNpc of PD brains 48.  Epidemiological studies strongly support 
the beneficial effect of NSAIDs in lowering the risk for developing PD 5;22;49. Nevertheless, 
NSAIDs are not widely recommended as a treatment for PD because they have many toxic 
effects 140;206. Besides NSAIDs there is no approved clinical drug that can slow or stop 
neurodegeneration in PD. 
One of the major challenges in the development of therapeutics for PD is the lack of 
biomarkers. Validated biomarkers would confirm the diagnosis, objectively determine pathology 
stages, and improve treatment efficacy by optimizing the temporal window for intervention. 
Biomarkers that indicate early phases of pathology are desired because early intervention may 
increase the chance for therapeutic success by preventing or halting neurodegeneration.  
PET imaging has been successfully employed for the last three decades in the assessment 
of neurological diseases, such as PD (reviewed in 207). Radiotracers designed for specific targets 
allow the characterization of different disease processes. Measurement of the in vivo distribution 
of these targets can reveal valuable information about their physiology and role in the disease 
state. Animal studies can take advantage of µPET as currently available µPET imaging systems 
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provide rat brain images of high resolution 144;145, while immunohistochemical analyses can 
confirm µPET findings by providing data at the cellular level 146.  
We established a rat model of neuroinflammation induced by PGJ2 that mimics 
hallmarks of PD pathology including activation of microglia and astrocytes commonly detected 
in the SN of PD brains 36;37;39. Immunohistochemistry analyses (Chapter 2, Fig. 2.4 and 2.5) 
showed that the PGJ2-treated rat brains exhibit activation of microglia and astrocytes at week 
four and eight post-injection, along with progressive neurodegeneration, a challenging aspect to 
model for PD. Therefore, the PGJ2 rat model of PD-like pathology can be used for longitudinal 
µPET studies and help identify biomarkers that may vary depending on the degree of the 
pathology. In collaboration with Weill Cornell Medicine (Dr. Anastasia Nikolopoulou, Dr. 
Yeona Kang, and Dr. John Babich), we visualized microglia and astrocyte activation in the 
PGJ2-treated rat brains. We used [11C]PK11195, a PET radiotracer that has been widely 
validated in clinical research for studying CNS disorders, including PD 208;209. 
3.3. MATERIALS AND METHODS 
3.3.1. Materials - The PGJ2 (cat. # 18500, Cayman Chemical) dosage used in the study was 33.4 
µg in 2 µL solution. The final DMSO concentration in PBS was 17% for all microinfusions. The 
solutions were freshly prepared and stored at 4°C and in the dark.  
3.3.2. Rats - All procedures were performed in accordance with the NIH Guidelines for the Care 
and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committees at Weill Cornell Medicine. Young adult Sprague Dawley male rats from Envigo 
(Frederick, MD) were used at 18 weeks of age at the time of the first injection. Rats were 
acclimated for one week before the surgery and had food and water available ad libitum on a 12-
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hour light/dark cycle.  
3.3.3. Stereotaxic surgery – Surgical procedures were followed as described in Chapter 2. All 
rats received unilateral microinfusions into the right side of the SN. No injections were given on 
the left side of the SN, which served as the internal control. Each rat received one injection per 
week for two weeks with DMSO or PGJ2 (33.4 µg in 2 µL DMSO).  
3.3.4. Groups - Rats were randomly assigned to the treatment groups (2X DMSO, N=4 or 2X 
PGJ2, N=3).  
3.3.5. µPET imaging – [11C]PK11195-PET was performed at week four and eight after the last 
intranigral injection [DMSO (vehicle) or PGJ2] using the Inveon® imaging system (Siemens 
Medical Solutions USA, Inc.). Each rat was first inserted with an i.v. catheter in the tail vein 
after induction of anesthesia (isoflurane at 3-4% in medical air for induction, and 2% for 
maintenance), and then placed in the transaxial position with its head in the center of the scanner 
field of view. The radiotracer (Dose: 1.0-1.5 mCi / 0.3-0.5 mL) was injected as a bolus over 20 
sec and a 60 min dynamic scan starts with 24 time frames. The emission data was reconstructed 
with OSEM2D (2 iterations, 16 subsets) with final images having a voxel size of 0.78×0.78×0.80 
mm. The T1-weighted MRI brain reference template was generated from normal rats using a 7T 
animal MRI scanner. The MRI template was co-registered to the corresponding µPET images 
and Region of Interests (ROIs) were manually drawn around SN onto the MRI template using 
the Paxinos and Watson 7th edition Rat Brain Atlas for guidance. For kinetic analysis, the Logan 
method was used and quantitative data was expressed as ratio of the volumes of distribution (VT) 
between the ipsilateral and the contralateral sides (ipsi/contra). 
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Adult Male Sprague-Dawley Rats
(18 weeks of age at the time of 1st injection)
PGJ2 [33.4 µg in (DMSO/PBS, 17 %)] or 
control (DMSO/PBS, 17 %) 
Unilateral injections (2 µL) into right SNpc
2X Injections: 
PGJ2 or
DMSO (Control)
µPET - [11C]PK11195
+ 4 weeks
+ 4 weeks
µPET - [11C]PK11195
Fig. 3.1. Schematic representation of the experimental design for µPET imaging. Eighteen-week-old 
male Sprague Dawley rats were microinjected twice into the right substantia nigra pars compacta 
(SNpc) with DMSO (control; 17% in PBS) or PGJ2 (33.4 µg) in 2 µL DMSO/PBS, at weekly intervals. 
Each rat was imaged at week four and eight after the last microinjection. 2X DMSO, N=4 or 2X PGJ2, 
N=3. 
63 
 
3.4. RESULTS 
3.4.1. PGJ2 induces chronic neuroinflammation that can be monitored in vivo with µPET 
imaging – DMSO and PGJ2-treated rats were imaged at week four and again at week eight after 
the last intranigral injection (Fig. 3.1). µPET images (Fig. 3.2) show the uptake and distribution 
of [11C]PK11195 in the rat brains. At week four post-injections, high radioactivity localization is 
observed in the injected side of the SN of treated rats. Radioactivity uptake is significantly higher 
in  PGJ2-treated rats compared to controls. At week eight post-injection, [11C]PK11195 uptake in 
the SN of PGJ2-treated brains is reduced compared to week four, but it is still significantly 
higher than control brains. Quantitative imaging data are summarized in Table 3.1.  
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[11C] PK11195 
scans 
2X, 4wks
(mean±SD)
2X, 8wks
(mean±SD) p-value (B) (%) Change
Control (N=4) 1.23±0.16 1.03±0.11 0.03 21.76% ↓
PGJ2 (N=3) 1.55±0.1 1.37±0.15 0.02 15.69% ↓
p-value (A) 0.01 0.02
Fig. 3.2. Glial activation induced by successive PGJ2 microinfusions is detected in vivo using 
[11C]PK11195. µPET images were taken from rats injected with DMSO or PGJ2. White arrows 
indicate the microinfusion sites. Coronal representative µPET images are shown. Increase in 
[11C]PK11195 binding was detected in PGJ2-treated compared to DMSO-treated rats. L and R, rat left 
and right sides, respectively. Table 3.1 - Volume Distribution (VT) ratios (ipsilateral / contralateral 
sides) for [11C]PK11195. PGJ2-treated rats exhibited significantly higher uptake of [11C]PK11195 in 
the injected (ipsilateral) side of the SN at both times compared to the control rats [p-value (A)]. 
[11C]PK11195 uptake is reduced at eight weeks compared to four weeks in both PGJ2 and control 
groups, but less in the PGJ2 group [p-value (B)]. N = 3-4 rats per group. The p values were 
established with the Student's T-test. The p values in red indicate significant (p<0.05) difference. 
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3.5. DISCUSSION 
In order to validate the use of µPET to image gliosis in the PGJ2-treated rat model, we 
used the radiotracer [11C]PK11195, which is a TSPO selective ligand. TSPO is one of the 
subunits of the mitochondrial permeability transition pore, and is found in many tissue types in 
the periphery as well as in the brain 208. Normally, TSPO levels are very low in the brain, but its 
mitochondrial expression increases in activated microglia and astrocytes upon brain injury or 
insult 210;211.  Therefore, TSPO serves as a marker for detection of glial activation 212.  
PD brains exhibit increased activation of microglia and astrocytes 26;27;29. During 
neuroinflammation, prolonged activation of microglia and astrocytes results in the release of 
various inflammatory mediators that further drive disease progression 30;31. µPET data acquired 
during these studies show that repeated PGJ2 injections induce chronic gliosis in the SN and is in 
agreement with the immunohistochemical results described in Chapter 2 (Fig. 2.4 and 2.5).  
Overall, our PET studies suggest that the PGJ2-induced rat model can be used to assess 
the progression of neuroinflammation via PET imaging. Novel radioligands specific for 
downstream factors of the COX pathway as identified in the studies discussed in Chapter 2, will 
help identify biomarkers for PD during disease progression, and identify the optimal window for 
therapeutic intervention.  
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Approximately 750,000 to one million people in the U.S. suffer from PD and there is no 
cure. The annual economic burden of PD is $19.8 to $26.4 billion and it is expected to rise with 
the growth of the aging population: the U.S. population over 50 years of age is estimated to 
increase by 46.2% over 30 years by the year 2040 213;214.  
 Since James Parkinson’s seminal paper 200 years ago on the first description of PD, our 
knowledge in many aspects of PD have greatly increased from clinical description and 
neuroanatomical pathology to physiological, cellular and molecular characteristics (reviewed in 
215), for which animal models have been instrumental. However, efforts to develop an animal 
model that reproduces all aspects of PD pathology still face many obstacles mainly because the 
exact causes of PD are unclear. Nevertheless, under the overarching multifactorial hypothesis of 
PD etiology, neuroinflammation is known to be crucial to PD neuropathology. Chronic 
neuroinflammation in particular promotes the progression of PD.  
 COX-2, found to be highly expressed in PD brains 48, is up-regulated by PGJ2 via a 
positive feedback loop 138;139. Therefore, our studies aimed to establish a rat model of PD based 
on chronic neuroinflammation induced by PGJ2, the most neurotoxic prostaglandin of the COX 
pathway that we tested. 
 Our studies show that the PGJ2-induced rat model of PD exhibits: (a) a dose-dependent 
and temporal progression of DA neuronal loss in the SNpc with non-significant effects on 
neurons in nearby brain regions, such as the VTA and the SNpr; (b) a motor deficit correlation 
with the loss of DA neurons in the SNpc; (c) microglia activation and sustained astrogliosis;                                          
(d) neuroinflammation  confirmed in vivo by µPET imaging using the radioligand [11C]PK11195 
at four weeks and eight weeks post the last PGJ2-injection; and (e) increased accumulation of 
ubiquitinated proteins and pS129 α-synuclein in potentially degenerating DA neurons.  
68 
 
 A five-week-long ibuprofen treatment, initiated on the next day following the first PGJ2 
injection, improved motor deficits and DA neuronal loss in the PGJ2-induced rat model of PD. 
Ibuprofen effectively reduced microglia activation, but had no significant preventive effect on 
astrogliosis. While epidemiological studies support the benefit of NSAID treatment in lowering 
PD risk, our findings with the PGJ2-induced rat model support that ibuprofen prevents DA 
neuronal loss. The protective effects of ibuprofen may depend on the dosage and timeline of 
treatment. 
 Based on our studies, we hypothesized that DA neuronal loss triggered by PGJ2-induced 
chronic neuroinflammation is driven by changes in the levels of COX pathway factors present in 
DA neurons and microglia. Our data suggest the following mechanisms and potential therapeutic 
approaches: 
 1) Targeting L-PGDS: Immunohistochemistry analyses showed that PGJ2-treated rats 
exhibited increased levels of COX-2 and L-PGDS, the brain synthase for PGD2 (PGJ2 
precursor), in microglia and DA neurons. This finding suggests that L-PGDS inhibitors that 
decrease brain PGD2 levels, have potential to protect neurons independently from DP receptor 
activation. This premise is supported by a study with cortical neurons cultured under hypoxic 
conditions 113. Accordingly, cortical neurons derived from L-PGDS null mice exhibited higher 
cell viability and less accumulation of ubiquitinated proteins than those derived from L-PGDS 
heterozygous mice. These hypoxia-driven effects were not prevented by the administration of 
DP1 or DP2 receptor antagonists 113. In addition, PGD2 synthesized by L-PGDS promotes cell 
migration and induces gliosis-like morphological changes as shown in mouse primary microglia 
and astrocyte cultures incubated with PGD2 108. In the same study, similar glial activation was 
observed when glial cultures were incubated with mouse recombinant L-PGDS, supporting that 
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L-PGDS affects glia as a secreted lipocalin-like ligand, independently of PGD2 108. Moreover, L-
PGDS injections into the striatum of mouse brains induced GFAP-positive astrocyte migration to 
the site of injection 108. Based on these studies, it is possible that down-regulating L-PGDS levels 
will lessen gliosis in the PGJ2-treated rats and reduce the neurotoxic consequences of PGJ2. 
Notably, PGD2 toxicity is mediated by its metabolites of the J-series prostaglandins 113. 
 2) Targeting the DP1 receptor: PGD2 and PGJ2 both induce cAMP upregulation by 
binding to the DP1 Gs-protein-coupled-receptor with comparable affinities 110;111. DP1 activation 
is reportedly neuroprotective, as shown in cultures and organotypic slices of rat hippocampus 
exposed to N-methyl-D-aspartic acid (NMDA) and glutamate-induced toxicity 101, in young and 
old mice undergoing NMDA-induced acute excitotoxicity 216, and in an ischemia mouse model 
217
. However, the use of DP1 agonists as neuroprotective agents must be approached with caution. 
Microglia and astrocytes also express DP1 receptors, thus DP1 agonists may amplify gliosis, 
which is an important point to consider in the light of the findings with AD brains. DP1 is 
significantly upregulated in AD brains and upregulated DP1 was localized in GFAP-positive 
activated astrocytes and reactive microglia within senile plaques 218. PGD2 enhances microglia 
activation via DP1 receptors, and PGD2 was reportedly responsible for sustaining degeneration 
of rat hippocampal neurons over 30 days after kainic acid (KA)-induced excitotoxicity 219. While 
further research is necessary to differentiate the beneficial and harmful types of activated 
astrocytes in relation to the DP1 pathway, neuronal damage mediated by activated microglia is 
known to be associated with DP1 activation 220.  
3) Targeting the DP2 receptor: Binding of PGD2 or PGJ2 to the DP2 Gi-protein-
coupled-receptor downregulates cAMP, increases intracellular calcium levels, and induces 
subsequent neurotoxicity 117. PGJ2 has a much higher affinity for DP2 than for DP1, the latter 
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playing a role in neuroprotection as described above. We established with the PGJ2-induced rat 
model that DP2 receptors are abundantly expressed in DA neurons in the SNpc, while almost 
lacking in microglia. Therefore, PGD2 produced by microglia can negatively affect DA neurons 
via the DP2 receptor. A similar microglia-neuron interaction via DP2 receptors in neurons was 
reported in a peripheral nerve injury rat model, in which DP2 antagonists [CAY10471 (Cayman 
Chemical, Ann Arbor, MI), and its BAY-u3405 (ramatroban) analog] attenuated the pain 195. In 
addition, CAY10471 was shown to increase survival of hippocampal neurons exposed to 
aluminum 196. Based on all of these findings, we predict that DP2 antagonists could potentially 
protect DA neurons from the damaging effects of activated microglia in the PGJ2-induced rat 
model.  
4) Targeting 15-PGDH: The key prostaglandin-degrading enzyme (15-PGDH) may be a 
potentially effective therapeutic target to counteract the neurotoxic effects of COX-2 
overexpression in PD. This notion is supported by cancer studies suggesting that COX-2 and 15-
PGDH reciprocally regulate each other 221;222, (reviewed in 223). COX-inhibiting NSAIDs 
reportedly increase 15-PGDH expression in cancer cells (reviewed in 122). However, COX-2 
inhibition by NSAIDs is not directly linked to15-PGDH up-regulation. Instead, NSAIDs appear 
to inhibit the protease responsible for the turnover of 15-PGDH (reviewed in 122).  
15-PGDH deactivates a wide variety of prostaglandins with different affinities 119. 
Therefore, the benefit of activating 15-PGDH to protect against neuroinflammation is more 
likely undermined by its lack of prostaglandin specificity, and by its potential higher affinity for 
neuroprotective prostaglandins than for PGD2 119. 
Finally, we found in the PGJ2-induced rat model that 15-PGDH levels in DA neurons 
remains relatively low compared to mature oligodendrocytes. High expression of 15-PGDH may 
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enable oligodendrocytes to be resilient to the neurotoxic effect of PGD2, and offset the 
neurotoxic effect of PGJ2. However, DA neurons in the SNpc are unmyelinated or thinly 
myelinated  6, and the role of oligodendrocytes may be limited to rescuing degenerating DA 
neurons in the SNpc via axon-myelin interactions 224;225.  
In conclusion, our findings suggest that the damaging effects of PGJ2/D2 could 
potentially be minimized by inhibiting L-PGDS and/or by blocking DP2 receptors. Overall, the 
PGJ2-induced rat model of neuroinflammation that we developed provides an optimal tool to 
study: (1) the relationship between PGJ2-induced chronic inflammation and neurodegeneration 
relevant to PD; (2) the in vivo progression of PD-like pathology with novel PET tracers; and (3) 
therapeutic strategies to ameliorate the susceptibility of DA neurons to neuroinflammation 
relevant to PD.   
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PD is characterized by progressive degeneration of the nigrostriatal pathway leading to 
motor deficits. The pathological hallmarks of PD are Lewy bodies, which are neuronal protein 
aggregates that contain, among other proteins, α-synuclein and ubiquitinated proteins. With the 
progression of the disease, the scope of affliction extends beyond the DA neurons in the SN, as 
heterogeneous non-motor deficits become also common (reviewed in 5 and 6).  
Chronic neuroinflammation is undoubtedly involved in the initiation and 
pathophysiology of PD, as supported by findings from GWAS 15;16, epidemiological 49 and post-
mortem tissue studies 19;25-27;29;48, as well as research with genetic and toxin-induced models of 
PD 75;76. One of the most pertinent aspects of neuroinflammation related to PD is the COX 
pathway. Aging is a major risk factor for PD 226-229, and COX activity increases with aging 78. 
Moreover, higher expression of COX-2 was reported in the ventral midbrain of PD patients 48, 
and variants of the cox-2 gene were found to be associated with PD 79;80. These cox-2 variants 
include a C8473T single nucleotide polymorphism (SNP) in the 3’-UTR region, and a -
1195G>A polymorphism in the promoter region 79;80. Epidemiological studies established that 
COX-inhibiting NSAIDs lower the risk and development of PD 49, though there has been no 
report on its successful replication in clinical settings. Challenges of replicating the 
epidemiological findings in clinical studies could be due to the adverse side effects of NSAIDs, 
insufficient period of use, and/or the older age of cohorts at the initial time of intervention 
(reviewed in204).  
 To address whether a product of the cyclooxygenase pathway could by itself induce PD-
like pathology, we established a rat model of neuroinflammation induced by PGJ2 
microinjections into the SNpc. We used the PGJ2-induced rat model to:  
(1) Establish an in vivo correlation between PGJ2 and PD-like pathology. 
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(2) Characterize, for the first time ever, the prostaglandin D2/J2 pathway in the SNpc, 
including COX-2, the PGD2 synthase L-PGDS, the DP2 receptor to which PGJ2 binds with a 
high affinity (nanomolar range) 117;118, and the prostaglandin dehydrogenase 15-PGDH. We 
investigated the impact of PGJ2-treatment on the distribution and levels of these elements of the 
prostaglandin D2/J2 pathway, in two major cell types in the SNpc: DA neurons and microglia. 
(3) Evaluate the potential of ibuprofen, a non-selective NSAID that inhibits both COX-1 
and COX-2, to prevent the PGJ2-induced PD-like pathology, including loss of DA neurons, 
motor deficits and gliosis (microglia and astrocytes). 
(4) Validate the longitudinal use of µPET imaging to assess the development of 
progressive gliosis in vivo. 
The PGJ2 rat model exhibited some of the essential characteristics of PD, including 
progressive DA neuronal loss in the SNpc with the concomitant motor deficits, microgliosis as 
well as astrogliosis, and the accumulation of ubiquitinated protein and phospho (pS129) α-
synuclein.  
Our findings on the distribution and levels of elements of the prostaglandin D2/J2 
pathway, suggest that antagonists for the PGJ2-binding DP2 receptor could be of therapeutic 
interest. The higher expression level of DP2 receptors in DA neurons compared to microglia, 
supports an enhanced neuronal vulnerability to PGD2/J2 mediated toxicity, as PGD2/J2 bind to 
DP2 with high affinity (nanomolar range). However, DP1 agonists, suggested by others to be 
neuroprotective, could be hazardous to neurons. Microglia and astrocytes also express DP1 
receptors, thus increases in PGD2/J2 levels could induce gliosis, ending up being harmful to 
neurons. Alternatively, down-regulating L-PGDS activity leading reduced PGD2/PGJ2 levels, 
could diminish PGD2/PGJ2-associated neurotoxicity and gliosis.  
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 We also established that ibuprofen diminishes the PD-like pathology induced by PGJ2, 
such as loss of DA neurons, motor deficits and microgliosis. Ibuprofen inhibits COX-1 and 
COX-2, and also binds and activates the peroxisome proliferator-activator receptor gamma 
(PPARγ). Activation of PPARγ has anti-inflammatory properties 230, and modulates immune 
proteins such as neuronal pentraxins 231. Which of these ibuprofen actions mediates its 
preventive effects in the PGJ2-induced rat model, remains to be investigated.  
 NSAIDs, including ibuprofen, target cyclooxygenases as well as the prostaglandin 
degrading enzyme 15-PGDH in an inversely related manner, as shown in cancer cells 121;122;222. 
Increased expression of 15-PGDH induced by NSAIDs may offset the effects of neurotoxic 
prostaglandins. Although 15-PGDH metabolizes neuroprotective as well as neurotoxic 
prostaglandins, higher 15-PGDH levels may be beneficial under conditions where the effects of 
neurotoxic prostaglandins outweigh those of the neuroprotective ones. 
Finally, µPET imaging with the TSPO radiotracer [11C]PK11195 showed that the levels 
of activated microglia and reactive astrocytes can be assessed in vivo in the PGJ2-induced rat 
model of neuroinflammation. We observed at two different post-injection time points (weeks 
four and eight), that PGJ2-treatment induced a significant unilateral progressive uptake of 
[11C]PK11195 in the SN. These data support that PGJ2, by itself, induces a rise in activated 
microglia and reactive astrocytes, which could be contributing to the progressive nature of PD. 
 Based on our findings we suggest the following research directions to further characterize 
the PGJ2-induced rat model of neuroinflammation relevant to PD, to validate its usefulness to 
investigate the progression of PD-like pathology in vivo, and to test novel PD therapeutic options:  
1. Characterize the types of activated astrocytes during chronic neuroinflammation – The 
PGJ2-induced rat model of neuroinflammation shows that PGJ2-treatment caused sustained 
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astrogliosis, which was not alleviated by the ibuprofen treatment. Post-mortem studies of PD 
brains confirm that significantly increased numbers of activated astrocytes are detected in the SN 
26;29
. The role of astrocytes in PD pathology is ambiguous as activated astrocytes can produce 
both pro-inflammatory and anti-inflammatory factors, as well as neurotoxic and neurotrophic 
factors (reviewed in 26). Thus, reactive astrocytes may exhibit two functional states: toxic (A1 
type) or trophic (A2 type). More research on this aspect of astrocyte function is required, but 
transcriptome analyses revealed different pathways of gene regulation in each type of reactive 
astrocytes 41. Identifying the type of activated astrocytes and their distribution in the PGJ2-
induced rat model of neuroinflammation could help establish the direction to target the reactive 
astrocytes in PD: whether to increase or reduce astrocyte activation to attain the best possible 
therapeutic benefit and potentially determine the most opportune time for therapeutic 
intervention.  
2. Investigate the distribution and levels of elements of the prostaglandin D2/J2 pathway in 
non-DA neurons outside the SNpc, and correlate them with PD-like symptoms at the 
molecular and behavior levels over longer periods of time – The PGJ2-induced rat model of 
neuroinflammation exhibits progressive DA neuronal degeneration in the SNpc, as confirmed by 
immunohistochemical analyses at four and eight weeks post the last PGJ2-injection. 
Furthermore, µPET studies with the dopamine transporter (DAT) radioligand [11C]PE2i showed 
that pre-synaptic neuronal degeneration progressively worsens in the PGJ2-treated rats until 26 
weeks post-injection (unpublished data by our Weill Cornell Medicine collaborators: Dr. 
Anastasia Nikolopoulou, Dr. Yeona Kang, and Dr. John Babich). Based on our studies, it is 
possible that disease progression is caused by toxic effects associated with the increased 
activation of microglia and sustained astrogliosis. We speculate that the observed persistent 
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gliosis is mediated by high levels of PGD2 and PGJ2 derived from L-PGDS, resulting in higher 
DP2 activation. Some of the mechanisms that could be triggered by higher PGD2/J2 levels and 
DP2 activation could include apoptosis, oxidative stress, mitochondrial dysfunction and 
abnormal protein modification. These processes are involved in the initiation and progression of 
PD associated with chronic neuroinflammation (reviewed in 24). It is important to investigate if 
these processes are induced in the PGJ2 rat model over a longer span of time, and if they mediate 
the spread of the disease to other brain regions beside the SNpc, as well as to non-DA neurons, 
and how they relate to non-motor PD-associated symptoms.  
3. Assess the progression of neuroinflammation linked to activated microglia and reactive 
astrocytes, and investigate their interactions in vivo by testing novel PET tracers – The 
TSPO  radioligand [11C]PK11195 has been widely used in CNS studies since the 1980s 
(reviewed in 232). The [11C]PK11195 signal has been considered to be specific for activated 
microglia during neuroinflammation associated with brain injuries as well as PD 233. More recent 
studies report that TSPO is also overexpressed in reactive astrocytes 234, which can thus be 
detected by PET imaging with [11C]PK11195 212. Therefore, the [11C]PK11195 signal detected in 
the PGJ2-treated rats represents the summation of both microglia and astrocyte activation. 
 Alternative radioligands are necessary to be able to discriminate between reactive 
astrocytes and activated microglia to study their temporal interactions along the progression of 
PD-like pathology. Radiotracer development for reactive astrocytes is still in a premature phase. 
235
 In contrast, various microglia targets are being explored and validated. For example, the 
purinergic receptor 2 ion channel receptor (P2X7R), is potentially specific to the pro-
inflammatory subtype of microglia, and is currently considered relevant to neurodegenerative 
diseases 236. P2X7R-targeting with [11C]GSK1482160 has been tested in LPS-treated mice and 
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may potentially serve as a neuroinflammatory biomarker 237.  
Additionally, in the PGJ2-induced rat model, in vivo assessment of elements of the 
prostaglandin D2/J2 pathway downstream of cyclooxygenases, could lead to the identification of 
novel PD biomarkers. For example, we speculate that µPET imaging with [18F] FBuEA-GS, a 
radio-labeled fluorobutyl ethacrynic glutathione conjugate amide, could be used as a potential 
biomarker for PD diagnosis. This radioligand specifically binds to L-PGDS, and has been used 
for imaging high-grade gliomas, which are brain tumors 200. [18F] FBuEA-GS could be used to 
detect L-PGDS changes in the SNpc DA neurons and microglia in PD patients. Using the PGJ2-
induced rat model, we could attempt to correlate L-PGDS level and glial activation or neuronal 
loss in vivo. The PGJ2-induced rat model of neuroinflammation is thus optimal to test such novel 
radioligands.  
4. Explore novel therapeutic strategies for PD – In the PGJ2-induced rat model, we 
characterized the distribution and levels of elements of the prostaglandin D2/J2 pathway, that 
included COX-2, the PGD2 synthase L-PGDS, the DP2 receptor, and the prostaglandin 
dehydrogenase 15-PGDH. Based on our data, we speculate that potential novel therapeutic 
strategies for PD could include inhibiting L-PGDS activity, stimulating the DP1 receptor, and 
blocking the DP2 receptor, to protect DA neurons in the SNpc against neurotoxicity associated 
with neuroinflammation. Future studies could test the following drugs: 
 1) AT-56 (4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-(2H-tetrazol-5-yl)-butyl]-
piperidine), a selective L-PGDS inhibitor. Previous studies showed that serum starvation 
increased PGD2 synthesis by ~2-fold in human-derived medulloblastoma cells (TE671), and that 
AT-56 treatment was effective in reducing PGD2 238. In another study, PGD2 levels were 
increased from 0.23 ng to 118 ng / brain in H-PGDS-deficient mice in response to a stab wound 
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239
. PGD2 levels were significantly reduced up to 40%, by oral treatment one hour prior to the 
injury, with AT-56  in a dose-dependent manner (3, 10, 30 mg / kg of AT-56) 239. Inflamed 
human enteric nervous system (ENS) expresses L-PGDS, not H-PGDS 240. In rat ENS primary 
cultures treated with LPS, AT-56 significantly reduced PGD2 synthesis 240. As gastrointestinal 
dysfunction is a very common symptom in PD 241, AT-56 may be used to investigate the 
relevance of L-PGDS to this non-motor type of PD pathology. 
 2) BW245C, a DP1-selective agonist. BW245C was shown to rescue rat hippocampal 
neuronal cultures from NMDA-induced toxicity by eliciting a rapid increase in the production of 
cAMP 101. Intracerebroventricular pre-treatment with BW245C (10 – 50 nM) lowered the 
NMDA-induced brain lesion size in young and old mice in a dose-dependent manner  216. 
However, the in vivo effect of BW245C must be considered with caution, as DP1 receptors are 
expressed not only in neurons but also in microglia and astrocytes 218. When mouse primary 
cortical neurons pre-treated with BW245C, were combined with primary microglia cultures, 
microglia activation was observed 220.  
 3) BAY-u3405 (ramatroban), a known antagonist of DP2 and thromboxane receptors. 
BAY-u3405 has been marketed for allergic rhinitis in Japan 242, and its analogue CAY10471 is a 
highly potent and selective DP2 antagonist 243. CAY10471 was shown to reduce pain in a rat 
model of neuropathic pain 195,  and to diminish aluminum-induced toxicity in rat primary 
hippocampal neuronal culture 196. Recent studies suggest that emotional impairment and 
depression-related behaviors are mediated by DP2-receptor activation 244. In these studies, 
intracerebroventricular injection of LPS caused anxiety and decreased social behavior in wild-
type mice, but DP2-deficient mice were protected 244. DP2-deficient mice were also resistant to 
chronic stress induced-depression resulting from chronic corticosterone treatment 245. The LPS-
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induced emotional behaviors in wild-type mice were reversed by both DP2 antagonists, 
administered systemically for ramatroban (30mg / kg) or via intracerebroventricular injections 
for CAY10471 (1 nM) 244. The corticosterone-induced depressive behavior was also significantly 
reduced by intraperitoneal (i.p.) injections of ramatroban (30mg / kg) 245. Considering the 
prevalence of anxiety and apathy (30% - 40%) and depression (15% – 50%) among PD patients 
246
, DP2 antagonists could be therapeutically effective to treat non-motor PD symptoms, in 
addition to preventing the SN DA neuronal loss associated with chronic neuroinflammation.  
 Taken together, these novel drugs could be tested alone or in combination with ibuprofen 
to improve therapeutic effectiveness against neuroinflammation, in relation to motor and non-
motor symptoms of PD. The progressive nature of neurodegeneration exhibited by the PGJ2-
induced rats offers an advantage for comparing the therapeutic effectiveness of novel drugs. As it 
develops progressive PD-like pathology, the PGJ2-induced rat model of neuroinflammation is an 
optimal model to expand our knowledge of PD progression, to test novel tracers for PET imaging 
in PD, and to develop new therapeutic targets and biomarkers for PD.  
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Fig. 5.1. Scheme depicting novel therapeutic agents and PET radiotracers (in green) that, based on 
our studies, could have potential to treat and diagnose PD. 1 - DP2 receptor antagonists: in the 
SNpc, DP2 receptors were detected in dopaminergic neurons but not in microglia. DP2 receptor 
activation leads to a decrease in cAMP and an increase in calcium. These effects mediate 
neurotoxicity induced by DP2 receptor activation. Thus, DP2 receptor antagonists could potentially 
prevent DA neurodegeneration. 2 – L-PGDS inhibitors: in the brain, this enzyme synthesizes PGD2 
from PGH2. PGD2 and its metabolite PGJ2 can be neurotoxic. Thus, decreasing L-PGDS activity will 
lower PGD2 levels and could prevent or diminish the neurotoxic effects of PGD2/J2 on dopaminergic 
neurons. 3 – L-PGDS radiotracer: L-PGDS is highly abundant in DA neurons, microglia, and CSF. 
The radiotracer [18F] FBuEA-GS has been used for PET analysis of high-grade gliomas. We propose 
that this radioligand could be an optimal reagent to assess changes in neuroinflammation linked to 
PD. COX 1 and 2, cyclooxygenase 1 and 2; L-PGDS, lipocalin prostaglandin D synthase; 15-PGDH, 
15-hydroxyprostaglandin dehydrogenase; [18F]FBuEA-GS, glutathione conjugate of fluorine-18-
labeled fluorobutyl ethacrynic amide; PPARγ, peroxisome proliferator-activated receptor gamma; PET, 
positron emission tomography. For more details see chapter 5. 
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